{"content":"<li class=\"n-box-item date-title\" data-end=\"1512536399\" data-start=\"1512450000\" data-txt=\"Monday, December 23, 2019\">Tuesday, December  5, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3316517\" data-ts=\"1512532335\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316517-new-fed-nominee-no-fan-of-paper-money-bitcoin-pushes-through-12k-13k-14k\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Fed nominee no fan of paper money; Bitcoin pushes through $12K, $13K, $14K</a></h4><ul><li>&ldquo;Is Marvin Goodfriend the Worst Fed Nominee of All Time,\" goes the title of a post <a href=\"https://mises.org/wire/marvin-goodfriend-worst-fed-nominee-all-time\" target=\"_blank\">on&nbsp;the website</a> of the Mises Institute.</li><li>Goodfriend has <a href=\"https://www.bloomberg.com/news/articles/2017-12-05/trump-s-latest-pick-for-the-fed-is-no-fan-of-paper-money\" target=\"_blank\">shown more than an academic interest</a> in eliminating currency, arguing the existence of cash makes it difficult for the Fed to impose negative interest rates. In a paper he presented at Jackson Hole last year, Goodfriend suggested abolishing currency as a way to force consumers to keep money in banks (at negative rates).</li><li>If that doesn't work, he says, consider interest rates of negative 10% not just cutting the value of $1 on deposit to $0.90, but also cutting the value of a $1 bill in your pocket to $0.90.</li><li>Not enough? How about \"currency cards\" which represent money straight from the central bank, from which the Fed could electronically control its value.</li><li>Bitcoin this evening has blasted through $12K for the first time, now&nbsp;<font color='green'>up more than 5%</font>&nbsp;on the session to $12,272. Coincidence?</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/UBIA' title='UBI BlockChain Internet Ltd.'>OTC:UBIA</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, PRELF, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a></li><li><strong>Update at 3:00 ET:</strong> Now&nbsp;<font color='green'>higher by 12%&nbsp;</font>for the session, Bitcoin has topped $13K as well.</li><li><strong>Update at 8:45 ET:</strong> The surge has continued, with Bitcoin now north of $14K.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316517\" data-linked=\"New Fed nominee no fan of paper money; Bitcoin pushes through $12K, $13K, $14K\" data-tweet=\"$GBTC $GBTC $COIN - New Fed nominee no fan of paper money; Bitcoin pushes through $12K, $13K, $14K https://seekingalpha.com/news/3316517-new-fed-nominee-no-fan-of-paper-money-bitcoin-pushes-through-12k-13k-14k?source=tweet\" data-url=\"https://seekingalpha.com/news/3316517-new-fed-nominee-no-fan-of-paper-money-bitcoin-pushes-through-12k-13k-14k\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>92&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316508\" data-ts=\"1512517055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TROX\" target=\"_blank\">TROX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316508-tronoxminus-10-ftc-challenges-proposed-merger-cristal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tronox -10% as FTC challenges proposed merger with Cristal</a></h4><ul>     <li>Tronox (NYSE:<a href='https://seekingalpha.com/symbol/TROX' title='Tronox Inc.'>TROX</a>) <font color='red'>-9.9%</font> after-hours as the Federal Trade Commission <a href=\"https://www.ftc.gov/news-events/press-releases/2017/12/ftc-challenges-proposed-merger-major-titanium-dioxide-companies\" target=\"_blank\">issues an administrative complaint</a> challenging its proposed acquisition of competitor Cristal, which would combine two of the top three U.S. suppliers of chloride process titanium dioxide.</li>     <li>The FTC alleges that the acquisition would allow the newly merged firm and the other top supplier, Chemours (NYSE:<a href='https://seekingalpha.com/symbol/CC' title='The Chemours Company'>CC</a>), to control the vast majority of chloride titanium dioxide sales in the North American market and more than 80% of North American chloride titanium dioxide manufacturing capacity.</li>     <li>The FTC says an administrative trial will begin on May 8, 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316508\" data-linked=\"Tronox -10% as FTC challenges proposed merger with Cristal\" data-tweet=\"$TROX $TROX $CC - Tronox -10% as FTC challenges proposed merger with Cristal https://seekingalpha.com/news/3316508-tronoxminus-10-ftc-challenges-proposed-merger-cristal?source=tweet\" data-url=\"https://seekingalpha.com/news/3316508-tronoxminus-10-ftc-challenges-proposed-merger-cristal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316507\" data-ts=\"1512514785\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AET\" target=\"_blank\">AET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316507-wsj-outgoing-aetna-ceo-bertolini-set-to-reap-500m-cvs-deal-closes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">WSJ: Outgoing Aetna CEO Bertolini set to reap ~$500M if CVS deal closes</a></h4><ul>     <li>Aetna (NYSE:<a href='https://seekingalpha.com/symbol/AET' title='Aetna, Inc.'>AET</a>) CEO Mark Bertolini <a href=\"https://www.wsj.com/articles/aetnas-outgoing-ceo-set-to-reap-about-500-million-if-cvs-deal-closes-1512480623\" target=\"_blank\">could pocket ~$500M when he leaves the company</a> if it successfully <a href=\"https://seekingalpha.com/news/3316085-cvs-finance-aetna-deal-65_8b-new-debt-equity-shares-5-percent\" target=\"_blank\">merges</a> with CVS Health, <em>WSJ</em> reports.</li>     <li>Most of Bertolini&rsquo;s anticipated payout is tied to stock or rights he already held that jump in value with the deal; at the $207/share deal price, more than $230M is expected to come from already vested stock appreciation rights he holds for AET shares, and common shares he currently owns would be valued at ~$190M at the deal price.</li>     <li>Some of the payout will be in CVS shares - which, of course, can fluctuate - because the acquisition was structured as 70% in cash and 30% in stock.</li>     <li>Another $60M-$85M of the estimated payout is tied to Bertolini&rsquo;s change-in-control package, which is triggered if he is terminated when the company sells itself.</li>     <li>Bertolini will not have an executive role at CVS-Aetna, but he will have a seat on its board of directors; CVS CEO Larry Merlo will run the combined company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316507\" data-linked=\"WSJ: Outgoing Aetna CEO Bertolini set to reap ~$500M if CVS deal closes\" data-tweet=\"$AET - WSJ: Outgoing Aetna CEO Bertolini set to reap ~$500M if CVS deal closes https://seekingalpha.com/news/3316507-wsj-outgoing-aetna-ceo-bertolini-set-to-reap-500m-cvs-deal-closes?source=tweet\" data-url=\"https://seekingalpha.com/news/3316507-wsj-outgoing-aetna-ceo-bertolini-set-to-reap-500m-cvs-deal-closes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316505\" data-ts=\"1512513796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316505-aerovironmentplus-19-after-posting-unexpected-quarterly-profit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment +19% after posting unexpected quarterly profit</a></h4><ul>     <li>AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>) <font color='green'>+19.3%</font> after-hours as it handily beats <a href=\"https://seekingalpha.com/news/3316467-aerovironment-beats-0_35-beats-revenue\" target=\"_blank\">FQ2 earnings</a> and revenue estimates and reaffirms FY 2018 guidance.</li>     <li>FQ2 revenues rose 47% Y/Y to $73.8M, mostly the result of a $23.2M increase in sales from its unmanned aircraft systems segment; gross margin of $31M was 78% higher than in the year-ago quarter.</li>     <li>AVAV says orders for products and customer-funded R&amp;D programs boosted its funded backlog to $127M, a 49% increase over the prior quarter, \"significantly increasing our revenue visibility for the current fiscal  year.\"</li>     <li>For the full year, AVAV sees EPS of $0.45-$0.65 vs. $0.61 analyst consensus estimate on revenues of $280M-$300M vs. $294M consensus.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316505\" data-linked=\"AeroVironment +19% after posting unexpected quarterly profit\" data-tweet=\"$AVAV - AeroVironment +19% after posting unexpected quarterly profit https://seekingalpha.com/news/3316505-aerovironmentplus-19-after-posting-unexpected-quarterly-profit?source=tweet\" data-url=\"https://seekingalpha.com/news/3316505-aerovironmentplus-19-after-posting-unexpected-quarterly-profit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316504\" data-ts=\"1512513379\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316504-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a> <font color='green'>+18.1%</font>. <a href='https://seekingalpha.com/symbol/FNKO' title='Funko, Inc.'>FNKO</a> <font color='green'>+8.0%</font>. <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='green'>+7.0%</font>. <a href='https://seekingalpha.com/symbol/GLBL' title='TerraForm Global'>GLBL</a> <font color='green'>+3.7%</font>. <a href='https://seekingalpha.com/symbol/PZZA' title='Papa John&#39;s International, Inc.'>PZZA</a> <font color='green'>+3.9%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/LQDT' title='Liquidity Services, Inc.'>LQDT</a> <font color='red'>-16.5%</font>. BBG <font color='red'>-7.0%</font>. <a href='https://seekingalpha.com/symbol/VEEV' title='Veeva Systems Inc.'>VEEV</a>&nbsp;<font color='red'>-5.9%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/CEIX' title='CONSOL Energy Inc.'>CEIX</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a> <font color='red'>-3.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316504\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$AVAV $FNKO $PLAY - After Hours Gainers / Losers https://seekingalpha.com/news/3316504-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3316504-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316494\" data-ts=\"1512511015\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVNC\" target=\"_blank\">RVNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316494-revance-readies-175m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revance readies $175M equity offering</a></h4><ul><li>Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) <a href=\"https://seekingalpha.com/pr/17019265-revance-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a $175M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316494\" data-linked=\"Revance readies $175M equity offering\" data-tweet=\"$RVNC - Revance readies $175M equity offering https://seekingalpha.com/news/3316494-revance-readies-175m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316494-revance-readies-175m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:56 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316486\" data-ts=\"1512509709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316486-snap-slips-after-hours-evercore-gives-bearish-initiation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Snap slips after hours as Evercore gives bearish initiation</a></h4><ul>   <li>Shares in Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>), which peeled off a <font color='green'>10% gain</font> today after a <a href=\"https://seekingalpha.com/news/3316316-barclays-upgrades-snap-raises-price-target\" target=\"_blank\">boost to Overweight</a> at Barclays, have <font color='red'>fallen back 1.5%</font> after hours as Evercore ISI goes more bearish.</li>    <li>The firm has started Snap at Underperform and given it a low price target of $7 -- 53% downside from today's close.</li>    <li>Most analysts are Neutral-equivalent on the company as it tries to compete with Facebook on ad products.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316486\" data-linked=\"Snap slips after hours as Evercore gives bearish initiation\" data-tweet=\"$SNAP - Snap slips after hours as Evercore gives bearish initiation https://seekingalpha.com/news/3316486-snap-slips-after-hours-evercore-gives-bearish-initiation?source=tweet\" data-url=\"https://seekingalpha.com/news/3316486-snap-slips-after-hours-evercore-gives-bearish-initiation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316485\" data-ts=\"1512509594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VKTX\" target=\"_blank\">VKTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316485-viking-therapeutics-initiates-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viking Therapeutics initiates equity offering</a></h4><ul><li>Viking Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/VKTX' title='Viking Therapeutics'>VKTX</a>) <a href=\"https://seekingalpha.com/pr/17019228-viking-therapeutics-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of common stock. Price, volume and terms have yet to be announced.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>23%</font>&nbsp;premarket on robust volume on Wednesday, December 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316485\" data-linked=\"Viking Therapeutics initiates equity offering\" data-tweet=\"$VKTX - Viking Therapeutics initiates equity offering https://seekingalpha.com/news/3316485-viking-therapeutics-initiates-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316485-viking-therapeutics-initiates-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316484\" data-ts=\"1512509525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HPR\" target=\"_blank\">HPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316484-bill-barrett-to-merge-fifth-creek-energy-launch-21m-share-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bill Barrett to merge with Fifth Creek Energy, launch 21M-share offering</a></h4><ul>     <li>Bill Barrett (BBG) <font color='red'>-8.9%</font> after-hours as it announces a merger with Fifth Creek Energy Co. in a deal valued at $649M, creating an E&amp;P company focused on oil-weighted rural areas in Colorado's DJ Basin.</li>     <li>BBG and Fifth Creek each will become subsidiaries of a newly formed, publicly listed holding company; BBG stockholders will exchange their shares for the new company's stock on a one-for-one basis, and Fifth Creek's current sole owner will receive 100M shares of the new stock.</li>     <li>BBG says initial 2018 plans include operation of three drilling rigs on the combined acreage with anticipated 2018 production of 11M-12M boe (~65% oil) and capex of $500M-$600M.</li>     <li>Also, BBG says it will commence a <a href=\"https://seekingalpha.com/pr/17019172-bill-barrett-corporation-announces-public-offering-common-stock\" target=\"_blank\">public offering</a> of 21M common shares, with an underwriters option to purchase up to another 3.15M shares.</li>     <li>BBG plans to use the proceeds from the offering for general corporate purposes, including to finance future capital expenditures.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316484\" data-linked=\"Bill Barrett to merge with Fifth Creek Energy, launch 21M-share offering\" data-tweet=\"$HPR - Bill Barrett to merge with Fifth Creek Energy, launch 21M-share offering https://seekingalpha.com/news/3316484-bill-barrett-to-merge-fifth-creek-energy-launch-21m-share-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316484-bill-barrett-to-merge-fifth-creek-energy-launch-21m-share-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316481\" data-ts=\"1512509453\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDIT\" target=\"_blank\">EDIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316481-editas-medicine-launches-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Editas Medicine launches equity offering</a></h4><ul><li>Editas Medicine (NASDAQ:<a href='https://seekingalpha.com/symbol/EDIT' title='Editas Medicine'>EDIT</a>) <a href=\"https://seekingalpha.com/pr/17019225-editas-medicine-inc-announces-offering-common-stock\" target=\"_blank\">initiates</a> a $50M public offering of common stock. Price, volume and terms have yet to be announced.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316481\" data-linked=\"Editas Medicine launches equity offering\" data-tweet=\"$EDIT - Editas Medicine launches equity offering https://seekingalpha.com/news/3316481-editas-medicine-launches-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316481-editas-medicine-launches-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316480\" data-ts=\"1512509348\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GWPH\" target=\"_blank\">GWPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316480-gw-pharma-readies-equity-offering-shares-down-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GW Pharma readies equity offering; shares down 4% after hours</a></h4><ul><li>GW Pharmaceuticals plc (NASDAQ:<a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>) <a href=\"https://seekingalpha.com/pr/17019164-gw-pharmaceuticals-announces-proposed-public-offering-adss\" target=\"_blank\">launches</a> a public offering of $225M in American Depositary Shares (ADSs). Price, volume and terms have yet to be released. Shares are down&nbsp;<font color='red'>4%</font>&nbsp;after hours on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316480\" data-linked=\"GW Pharma readies equity offering; shares down 4% after hours\" data-tweet=\"$GWPH - GW Pharma readies equity offering; shares down 4% after hours https://seekingalpha.com/news/3316480-gw-pharma-readies-equity-offering-shares-down-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3316480-gw-pharma-readies-equity-offering-shares-down-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:29 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316469\" data-ts=\"1512508774\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNET\" target=\"_blank\">VNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316469-chinas-21vianet-groupminus-4_4-losses-widen-on-impairments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">China&#39;s 21Vianet Group -4.4% as losses widen on impairments</a></h4><ul>   <li>Data center service provider 21Vianet Group's (NASDAQ:<a href='https://seekingalpha.com/symbol/VNET' title='21Vianet Group'>VNET</a>) ADS are <font color='red'>off 4.4%</font> after hours after <a href=\"https://seekingalpha.com/news/3316451-21vianet-group-epads-line-misses-revenue\" target=\"_blank\">Q3 earnings</a> featured revenues that slipped 9% as the company disposed of its managed network services business.</li>    <li>The divestiture of MNS is a \"milestone development, which will enable us to re-focus on our IDC business and strengthen our core competitive power,\" says CEO Steve Zhang.</li>    <li>Gross profit was up 1.6% Y/Y, to 189.8M yuan (about $28.5M), and gross margin expanded to 21.4% from a year-ago 19.3%.</li>    <li>EBITDA nearly doubled to 135M yuan, about $20.3M, and EBITDA margin rose to 15.2% from 7%. Meanwhile, net loss swelled to 1.48B yuan (about $222.3M) from a year-ago 171.5M yuan, mainly due to impairments of long-lived assets and goodwill (excluding those, net loss was 130.8M yuan).</li>    <li>Monthly recurring revenues per cabinet rose to 8,571 yuan from 8,311; total cabinets under management increased to 27,424 from last quarter's 27,361. Utilization rate was 74.4% (down from last quarter's 75.2%) and hosting churn rate rose to 0.97% from last quarter's 0.24%.</li>    <li>Revenue breakout: Hosting and related services, 759.3M yuan (up 8.7%); Managed network services, 126.8M yuan (down 53%).</li>    <li>With its MNS business divested, the company's only guiding for its hosting and related services business, where it forecasts Q4 revenues of 740M-760M yuan vs. a year-ago 703.2M yuan. EBITDA for the business is forecast at 160M-170M yuan, vs. a year-ago 129.7M yuan.</li>    <li><a href=\"http://ir.21vianet.com\" target=\"_blank\">Conference call</a> to come at 8 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17019169-21vianet-group-inc-reports-unaudited-third-quarter-2017-financial-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3316469\" data-linked=\"China&#39;s 21Vianet Group -4.4% as losses widen on impairments\" data-tweet=\"$VNET - China&#39;s 21Vianet Group -4.4% as losses widen on impairments https://seekingalpha.com/news/3316469-chinas-21vianet-groupminus-4_4-losses-widen-on-impairments?source=tweet\" data-url=\"https://seekingalpha.com/news/3316469-chinas-21vianet-groupminus-4_4-losses-widen-on-impairments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:19 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316467\" data-ts=\"1512508696\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVAV\" target=\"_blank\">AVAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316467-aerovironment-beats-0_35-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AeroVironment beats by $0.35, beats on revenue</a></h4><ul><li>AeroVironment (NASDAQ:<a href='https://seekingalpha.com/symbol/AVAV' title='AeroVironment, Inc.'>AVAV</a>): Q2 EPS of $0.29 <font color='green'>beats by $0.35</font>.</li><li>Revenue of $73.8M (+47.2% Y/Y) <font color='green'>beats by $10.27M</font>.</li><li>Shares <font color='green'>+7%</font>.</li><li><a href='https://seekingalpha.com/pr/17019203-aerovironment-inc-announces-fiscal-2018-second-quarter-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3316467\" data-linked=\"AeroVironment beats by $0.35, beats on revenue\" data-tweet=\"$AVAV - AeroVironment beats by $0.35, beats on revenue https://seekingalpha.com/news/3316467-aerovironment-beats-0_35-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3316467-aerovironment-beats-0_35-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316445\" data-ts=\"1512507249\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VNOM\" target=\"_blank\">VNOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316445-viper-energy-partners-poised-for-permian-growth-upgraded-to-buy-ubs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Viper Energy Partners, poised for Permian growth, upgraded to Buy at UBS</a></h4><ul>     <li>Viper Energy Partners (<a href='https://seekingalpha.com/symbol/VNOM' title='Viper Energy Partners LP'>VNOM</a> <font color='green'>+1.7%</font>) is <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+UBS+Upgrades+Viper+Energy+%28VNOM%29+to+Buy%2C+Underappreciated+Distribution+Growth/13567932.html\" target=\"_blank\">upgraded to Buy</a> from Neutral with a $27 price target, raised from $19, at UBS, which believes VNOM is well positioned for growth through higher oil and gas production in the Permian Basin with 22 active rigs on its acreage, up from 18 in Q2.</li>     <li>The energy team at UBS increases its production estimates for VNOM by a respective 5% and 6% for 2018 and 2019 as it raises its 2018 and 2019 crude price forecast by a respective 6% and 2%.</li><li>As a result, UBS hikes its distribution growth expectations for VNOM and now expects a 2017-21 DPU compound annual growth rate of 17% (without additional acquisitions), up from 6%.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316445\" data-linked=\"Viper Energy Partners, poised for Permian growth, upgraded to Buy at UBS\" data-tweet=\"$VNOM - Viper Energy Partners, poised for Permian growth, upgraded to Buy at UBS https://seekingalpha.com/news/3316445-viper-energy-partners-poised-for-permian-growth-upgraded-to-buy-ubs?source=tweet\" data-url=\"https://seekingalpha.com/news/3316445-viper-energy-partners-poised-for-permian-growth-upgraded-to-buy-ubs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316442\" data-ts=\"1512506201\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FSLR\" target=\"_blank\">FSLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316442-first-solarplus-7-unveils-first-functional-series-6-module-2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">First Solar +7% as it unveils first functional Series 6 module, 2018 guidance</a></h4><ul>     <li>First Solar (<a href='https://seekingalpha.com/symbol/FSLR' title='First Solar, Inc.'>FSLR</a> <font color='green'>+6.8%</font>) surges after unveiling the <a href=\"https://seekingalpha.com/pr/17018907-first-solar-presents-first-functional-series-6-module\" target=\"_blank\">first functional Series 6 thin film photovoltaic module</a> produced at the company&rsquo;s Perrysburg, Ohio, facility and FY 2018 financial guidance.</li>     <li>FSLR tells its Analyst Day event that it expects Series 6 will enter the commercial market with a power rating of 420-445 watts and conversion efficiency of more than 17%, provide more watts per lift than comparable crystalline silicon solar panels, and can be installed on virtually any ground-based PV mounting system.</li>     <li>FSLR says it is expanding its production facility in Vietnam, essentially doubling production capacity of the initial site, which is still under construction; when fully operational, annualized production capacity in Vietnam will total 2.4 GW - when combined with Perrysburg and facilities in Malaysia, FSLR says its Series 6 manufacturing capacity will total ~5.4 GW by 2020.</li><li>The company also announces two module supply agreements (<a href=\"https://seekingalpha.com/pr/17018904-first-solar-origis-energy-confirm-module-sale-agreement\" target=\"_blank\">I</a>, <a href=\"https://seekingalpha.com/pr/17018897-first-solar-d-e-shaw-renewable-investments-ink-module-deal\" target=\"_blank\">II</a>) totaling nearly 800  MW with D. E. Shaw Renewable Investments and&nbsp;Origis  Energy USA.</li>     <li>In its financial guidance, FSLR sees FY 2018 GAAP EPS of $1.25-$1.75 vs $1.22 analyst consensus estimate and revenues of $2.3B-$2.5B vs $2.39B consensus.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3316442\" data-linked=\"First Solar +7% as it unveils first functional Series 6 module, 2018 guidance\" data-tweet=\"$FSLR - First Solar +7% as it unveils first functional Series 6 module, 2018 guidance https://seekingalpha.com/news/3316442-first-solarplus-7-unveils-first-functional-series-6-module-2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316442-first-solarplus-7-unveils-first-functional-series-6-module-2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316434\" data-ts=\"1512504814\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316434-microsoft-unveils-laptops-featuring-qualcomm-chips\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microsoft unveils laptops featuring Qualcomm chips</a></h4><ul>     <li>Microsoft (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>) <a href=\"https://www.cnbc.com/2017/12/05/microsoft-shows-first-windows-10-pcs-on-qualcomm-and-arm.html\" target=\"_blank\">shows off</a> new laptops built by Asus and HP with Qualcomm&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) ARM-based Snapdragon 835 chips.</li><li>               Windows PCs have traditionally used Intel (NASDAQ:<a href='https://seekingalpha.com/symbol/INTC' title='Intel Corporation'>INTC</a>) chips and Intel is watching closely to see if the Qualcomm chip inclusion violates its IP rights.&nbsp;</li><li>               Microsoft&rsquo;s last go with an ARM-based PC came in 2012 with the first-gen Surface tablets, which led to a $900M write-down the following year.&nbsp;</li><li>               Qualcomm needs partnerships as its legal battles with Apple continue and could lead to the end of that supplier agreement.&nbsp;</li><li>               Microsoft shares are&nbsp;<font color='green'>up 1%</font>.&nbsp;</li><li>               Qualcomm shares are&nbsp;<font color='green'>up 0.4%</font>. &nbsp;&nbsp;</li><li>               Intel shares are&nbsp;<font color='red'>down 2.4%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3305893-apple-drop-qualcomm-components\" target=\"_blank\">Apple could drop Qualcomm components</a> (Oct. 31)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3313254-fast-company-apple-intel-working-together-5g-modem\" target=\"_blank\">Fast Company: Apple and Intel working together on 5G modem</a> (Nov. 17)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3272644-intel-warns-qualcomm-microsoft-x86-architecture-emulation\" target=\"_blank\">Intel warns Qualcomm, Microsoft on x86 architecture emulation</a> (June 9)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316434\" data-linked=\"Microsoft unveils laptops featuring Qualcomm chips\" data-tweet=\"$MSFT $MSFT $QCOM - Microsoft unveils laptops featuring Qualcomm chips https://seekingalpha.com/news/3316434-microsoft-unveils-laptops-featuring-qualcomm-chips?source=tweet\" data-url=\"https://seekingalpha.com/news/3316434-microsoft-unveils-laptops-featuring-qualcomm-chips\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>80&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316430\" data-ts=\"1512503883\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316430-technology-top-gainers-losers-of-2-55-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:55 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/JRJC' title='China Finance Online Co. Limited'>JRJC</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/VHC' title='VirnetX Holding Corporation'>VHC</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BITA' title='Bitauto Holdings Limited'>BITA</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/PRKR' title='ParkerVision, Inc.'>OTC:PRKR</a> <font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316430\" data-linked=\"Technology - Top Gainers / Losers as of 2:55 pm\" data-tweet=\"$DPW $JRJC $VHC - Technology - Top Gainers / Losers as of 2:55 pm https://seekingalpha.com/news/3316430-technology-top-gainers-losers-of-2-55-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3316430-technology-top-gainers-losers-of-2-55-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316429\" data-ts=\"1512503861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVNC\" target=\"_blank\">RVNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316429-allergan-plays-down-revance-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan plays down Revance data</a></h4><ul><li>The response rates for Revance's (<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a> <font color='green'>+36.3%</font>) Phase 3 study of RT-002 were similar or worse than the Phase 2b study, Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-1.4%</font>) tells Bloomberg.</li><li>\"At 6 months, the response rate by physician assessment was only 29%-35%, and the response rate by patient assessment was only 22% at 6 months,\" says the company. Turning that around means nearly 80% of RT-002 patients did not feel they had maintained a response at six months.</li><li>\"We do not believe this data will support a longer duration claim.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316333-allergan-modest-pressure-potential-encroachment-revance-botox-franchise-shares-2-percent\" target=\"_blank\">Allergan under modest pressure on potential encroachment of Revance on Botox franchise; shares down 2% premarket</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316429\" data-linked=\"Allergan plays down Revance data\" data-tweet=\"$RVNC $RVNC $AGN - Allergan plays down Revance data https://seekingalpha.com/news/3316429-allergan-plays-down-revance-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3316429-allergan-plays-down-revance-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316421\" data-ts=\"1512501784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHGE\" target=\"_blank\">BHGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316421-baker-hughes-credit-rating-cut-s-and-p\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baker Hughes credit rating cut at S&amp;P</a></h4><ul>     <li>Baker Hughes' (<a href='https://seekingalpha.com/symbol/BHGE' title='Baker Hughes, a GE company'>BHGE</a> <font color='red'>-1.6%</font>) credit rating is <a href=\"https://www.streetinsider.com/Credit+Ratings/UPDATE%3A+Baker+Hughes+%28BHGE%29+credit+rating+to+A-+from+A%2B%2C+Outlook+Watch+Negative+from+Stable/13570633.html\" target=\"_blank\">downgraded</a> to A- from A+ at Standard &amp;&nbsp;Poor's, reflecting the credit agency's revision of BHGE's group status to non-strategic from highly strategic following GE's reassessment that it could look to exit its ownership in the company.</li>     <li>The outlook is stable, reflecting S&amp;P's expectation that BHGE will continue to achieve operating synergies from the merger with GE Oil &amp; Gas, projected to be up to $1.6B by 2020.</li>     <li>S&amp;P expects BHGE to benefit from a recovery in North American onshore markets at least over the next few years, which should offset weaker markets in the offshore and LNG markets until 2020 or later.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316421\" data-linked=\"Baker Hughes credit rating cut at S&amp;P\" data-tweet=\"$BHGE $BKR - Baker Hughes credit rating cut at S&amp;P https://seekingalpha.com/news/3316421-baker-hughes-credit-rating-cut-s-and-p?source=tweet\" data-url=\"https://seekingalpha.com/news/3316421-baker-hughes-credit-rating-cut-s-and-p\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316418\" data-ts=\"1512500990\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316418-bitcoin-investment-trust-premium-narrows\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bitcoin Investment Trust premium narrows</a></h4><ul><li>Bitcoin is having a relatively quiet day - currently unchanged - but not so for Bitcoin Investment Trust (<a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>). A plunge <a href=\"https://pbs.twimg.com/media/DQTJ14EVAAAuuSC.jpg\" target=\"_blank\">earlier this sessio</a>n narrowed the premium to the value of its Bitcoin holdings to about 40% from 80%.</li><li>The stock has since bounced, but still remains<font color='red'> lower by 10.5%&nbsp;</font>on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316418\" data-linked=\"Bitcoin Investment Trust premium narrows\" data-tweet=\"$GBTC $BTC-USD - Bitcoin Investment Trust premium narrows https://seekingalpha.com/news/3316418-bitcoin-investment-trust-premium-narrows?source=tweet\" data-url=\"https://seekingalpha.com/news/3316418-bitcoin-investment-trust-premium-narrows\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>136&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316417\" data-ts=\"1512500665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTGN\" target=\"_blank\">VTGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316417-vistagen-nabs-u-s-patent-covering-methods-of-synthesizing-compounds-shares-ahead-28\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VistaGen nabs U.S. patent covering methods of synthesizing compounds; shares ahead 28%</a></h4><ul><li>Thinly traded nano cap VistaGen Therapeutics (<a href='https://seekingalpha.com/symbol/VTGN' title='VistaGen Therapeutics, Inc.'>VTGN</a> <font color='green'>+28.2%</font>) jumps on lower-than-normal volume in apparent response to the issuance of a <a href=\"http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&amp;Sect2=HITOFF&amp;d=PALL&amp;p=1&amp;u=/netahtml/PTO/srchnum.htm&amp;r=1&amp;f=G&amp;l=50&amp;s1=9,834,801\" target=\"_blank\">new U.S. patent</a> (No. 9,834,801) covering methods of synthesizing compounds, including chiral kynurenines.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316417\" data-linked=\"VistaGen nabs U.S. patent covering methods of synthesizing compounds; shares ahead 28%\" data-tweet=\"$VTGN - VistaGen nabs U.S. patent covering methods of synthesizing compounds; shares ahead 28% https://seekingalpha.com/news/3316417-vistagen-nabs-u-s-patent-covering-methods-of-synthesizing-compounds-shares-ahead-28?source=tweet\" data-url=\"https://seekingalpha.com/news/3316417-vistagen-nabs-u-s-patent-covering-methods-of-synthesizing-compounds-shares-ahead-28\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316416\" data-ts=\"1512500566\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316416-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ZN' title='Zion Oil & Gas Inc'>ZN</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/CRK' title='Comstock Resources Inc.'>CRK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SE' title='Sea Ltd'>SE</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/VHI' title='Valhi, Inc.'>VHI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/NGL' title='NGL Energy Partners LP'>NGL</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/ASM' title='Avino Silver & Gold Mines Ltd'>ASM</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316416\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$ZN $CRK $SE - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3316416-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3316416-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316413\" data-ts=\"1512500051\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316413-adamis-up-26-on-ind-filing-for-opioid-overdose-drug-naloxone-symject-syringe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis up 26% on IND filing for opioid overdose drug naloxone with Symject syringe</a></h4><ul><li>Adamis Pharmaceuticals (<a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='green'>+26.2%</font>) is up on almost double normal volume in response to its <a href=\"https://seekingalpha.com/pr/17017565-adamis-pharmaceuticals-announces-submission-investigational-new-drug-ind-application-fda-new\" target=\"_blank\">IND filing</a> for opioid overdose antidote naloxone administered via the same patented Symject syringe delivery platform as emergency allergic reaction med Symjepi (epinephrine).</li><li>Clinical testing can start after the FDA approves the IND.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316413\" data-linked=\"Adamis up 26% on IND filing for opioid overdose drug naloxone with Symject syringe\" data-tweet=\"$ADMP - Adamis up 26% on IND filing for opioid overdose drug naloxone with Symject syringe https://seekingalpha.com/news/3316413-adamis-up-26-on-ind-filing-for-opioid-overdose-drug-naloxone-symject-syringe?source=tweet\" data-url=\"https://seekingalpha.com/news/3316413-adamis-up-26-on-ind-filing-for-opioid-overdose-drug-naloxone-symject-syringe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:54 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316411\" data-ts=\"1512498476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSPR\" target=\"_blank\">NSPR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316411-inspiremds-cguard-eps-shows-durable-effect-in-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InspireMD&#39;s CGuard EPS shows durable effect in study</a></h4><ul><li>A clinical study, PARADIGM 101, evaluating the long-term effect of InspireMD's (<a href='https://seekingalpha.com/symbol/NSPR' title='InspireMD, Inc.'>NSPR</a> <font color='red'>-5.6%</font>) <a href=\"http://www.inspiremd.com/en/product/cguard/\" target=\"_blank\">CGuard</a> embolic prevention system &#40;EPS&#41; showed a sustained treatment benefit. The results were presented at the ICI Meeting in Tel Aviv.</li><li>At 24 months of follow-up, no major adverse cardiac events (heart attack, stroke, death) occurred related to the placement of the stent.</li><li>Investors appear unmoved. Shares have sold off ~66% since last week.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316411\" data-linked=\"InspireMD&#39;s CGuard EPS shows durable effect in study\" data-tweet=\"$NSPR - InspireMD&#39;s CGuard EPS shows durable effect in study https://seekingalpha.com/news/3316411-inspiremds-cguard-eps-shows-durable-effect-in-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3316411-inspiremds-cguard-eps-shows-durable-effect-in-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:27 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316408\" data-ts=\"1512497364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDC\" target=\"_blank\">WDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316408-nikkei-toshiba-execs-meeting-to-settle-western-digital-dispute\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nikkei: Toshiba execs meeting to settle Western Digital dispute</a></h4><ul><li>        Toshiba execs will meet Wednesday to discuss settling with Western Digital (NYSE:<a href='https://seekingalpha.com/symbol/WDC' title='Western Digital Corporation'>WDC</a>), according to <a href=\"https://asia.nikkei.com/Business/Deals/Toshiba-to-map-out-end-game-of-Western-Digital-feud\" target=\"_blank\">Nikkei Asian Review</a>.</li><li>               The execs will discuss the &ldquo;sticking points&rdquo; that have prevented a resolution and the sale of Toshiba&rsquo;s chip unit.&nbsp;</li><li>                  Western Digital reportedly wants assurance that South Korean-based SK Hynix, a member of the buying consortium, won&rsquo;t have access to tech data from Toshiba Memory.    </li><li>               Western Digital is also worried about Bain, the consortium leader, and its desire to &ldquo;retain the option&rdquo; to sell Toshiba Memory to rivals like Samsung. &nbsp;&nbsp;&nbsp;&nbsp;</li><li>                  Western Digital shares are&nbsp;<font color='green'>up 1.5%</font>.&nbsp;&nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3315598-toshiba-western-digital-close-settling-dispute\" target=\"_blank\">Toshiba, Western Digital close to settling dispute</a> (Dec. 1)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316145-toshiba-will-sell-stake-chipmaker\" target=\"_blank\">Toshiba will sell most of its stake in chipmaker</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316408\" data-linked=\"Nikkei: Toshiba execs meeting to settle Western Digital dispute\" data-tweet=\"$WDC - Nikkei: Toshiba execs meeting to settle Western Digital dispute https://seekingalpha.com/news/3316408-nikkei-toshiba-execs-meeting-to-settle-western-digital-dispute?source=tweet\" data-url=\"https://seekingalpha.com/news/3316408-nikkei-toshiba-execs-meeting-to-settle-western-digital-dispute\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316406\" data-ts=\"1512496982\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPRI\" target=\"_blank\">CPRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316406-goldman-sachs-positive-on-michael-kors\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs positive on Michael Kors</a></h4><ul><li>Michael Kors (KORS <font color='green'>+1.9%</font>) trades higher after Goldman Sachs resumes coverage with a Buy rating.</li><li>Analyst Lindsay Drucker points to improving handbag trends and think synergies from the Jimmy Choo acquisition will accelerate.</li><li>GS assigns a price target of $70 to KORS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316406\" data-linked=\"Goldman Sachs positive on Michael Kors\" data-tweet=\"$CPRI - Goldman Sachs positive on Michael Kors https://seekingalpha.com/news/3316406-goldman-sachs-positive-on-michael-kors?source=tweet\" data-url=\"https://seekingalpha.com/news/3316406-goldman-sachs-positive-on-michael-kors\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316402\" data-ts=\"1512496791\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316402-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/JTPY' title='JetPay Corporation'>JTPY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316402\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$GROW $JTPY - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3316402-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3316402-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316405\" data-ts=\"1512496787\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316405-copper-price-plunges-amid-rising-inventories\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Copper price plunges amid rising inventories</a></h4><ul>     <li>Copper prices sink to their <a href=\"https://www.wsj.com/articles/metals-copper-tumbles-to-two-month-low-amid-rising-inventories-1512488851\" target=\"_blank\">lowest level in more than two months</a>, as some investors take profits following data showed an inflow into LME warehouses.</li>     <li>Comex copper for March delivery currently -4.4% at $2.952/lb. after falling below $3/lb. for the first time since early October and down more than 7% from three-year highs also reached last month.</li>     <li>After surging in response to strong Chinese economic data earlier this year, some investors now worry that a slowdown in China - which accounts for ~50% of the world&rsquo;s copper consumption - could weigh on prices moving forward, and has prompted some speculators to take chips off the table, says Jefferies analyst Christopher LaFemina.</li>     <li>A stronger dollar also is weighing on prices by making copper and other dollar-denominated commodities more expensive for overseas buyers.</li><li>Among big metals producers: <a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='red'>-2.2%</font>, <a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='red'>-2%</font>, <a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='red'>-1.4%</font>, <a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='red'>-1.2%</font>, <a href='https://seekingalpha.com/symbol/SCCO' title='Southern Copper Corporation'>SCCO</a> <font color='red'>-2.1%</font>, <a href='https://seekingalpha.com/symbol/TECK' title='Teck Resources Limited'>TECK</a> <font color='red'>-3.6%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/JJC' title='iPath Series B Bloomberg Copper Subindex Total Return ETN'>JJC</a>, <a href='https://seekingalpha.com/symbol/CPER' title='United States Copper Index ETF'>CPER</a>, <a href='https://seekingalpha.com/symbol/CUPM' title='iPath Pure Beta Copper ETN'>CUPM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3316405\" data-linked=\"Copper price plunges amid rising inventories\" data-tweet=\"$FCX $FCX $RIO - Copper price plunges amid rising inventories https://seekingalpha.com/news/3316405-copper-price-plunges-amid-rising-inventories?source=tweet\" data-url=\"https://seekingalpha.com/news/3316405-copper-price-plunges-amid-rising-inventories\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316400\" data-ts=\"1512496715\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDHL\" target=\"_blank\">RDHL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316400-redhill-to-part-ways-intelgenx-on-development-of-migraine-med-rizaport\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RedHill to part ways with IntelGenx on development of migraine med Rizaport</a></h4><ul><li>Citing its increasing focus on the GI space, RedHill Biopharma (<a href='https://seekingalpha.com/symbol/RDHL' title='RedHill Biopharma Ltd.'>RDHL</a> <font color='red'>-1.6%</font>) <a href=\"https://seekingalpha.com/pr/17018616-redhill-biopharma-provides-2017-year-end-business-update\" target=\"_blank\">informs </a>RIZAPORT (RHB-103) partner IntelGenx (<a href='https://seekingalpha.com/symbol/IGXT' title='IntelGenx Technologies Corp.'>OTCQX:IGXT</a> <font color='red'>-4.3%</font>) that it will terminate their co-development and commercialization agreement effective January 6, 2018. The companies announced the resubmission of the U.S. marketing application on November 1 but it appears the FDA issued either a CRL or Refusal-to-File letter in response. RedHill received the first CRL in March 2013.</li><li>In a update to investors, the company expects the following key events in 2018:</li><li>Topline results from the Phase 3 study of RHB-104 in Crohn's (mid-year).</li><li>Topline data from the Phase 3 study of TALICIA (RHB-105) in <em>H. pylori</em> infection&nbsp; (second half).</li><li>Initiation of Phase 3 study of RHB-104 in nontuberculous mycobacteria infections (first half).</li><li>Initiation of Phase 2a study of YELIVA (ABC294640) in bile duct cancer (early January).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306544-redhill-2-percent-premarket-refiling-u-s-marketing-application-rizaport-migraine\" target=\"_blank\">RedHill up 2% premarket on refiling of U.S. marketing application for Rizaport for migraine</a> (Nov. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316400\" data-linked=\"RedHill to part ways with IntelGenx on development of migraine med Rizaport\" data-tweet=\"$RDHL $RDHL $IGXT - RedHill to part ways with IntelGenx on development of migraine med Rizaport https://seekingalpha.com/news/3316400-redhill-to-part-ways-intelgenx-on-development-of-migraine-med-rizaport?source=tweet\" data-url=\"https://seekingalpha.com/news/3316400-redhill-to-part-ways-intelgenx-on-development-of-migraine-med-rizaport\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316399\" data-ts=\"1512496456\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/COUP\" target=\"_blank\">COUP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316399-barclays-comments-on-coupa-softwares-earnings-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays comments on Coupa Software&#39;s earnings report</a></h4><ul><li>        Barclays <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171205120457COUP\" target=\"_blank\">says</a> Coupa Software&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/COUP' title='Coupa Software Inc'>COUP</a>) earnings report yesterday showed healthy growth but that FY19 could have moving parts due to a shorter Q1 and adoption impact of 606.</li><li>               Firm thinks Coupa currently has a high valuation.&nbsp;</li><li>               Barclays reiterates its Equal Weight rating and $38 price target.&nbsp; &nbsp;&nbsp;</li><li>               Coupa shares are<font color='green'> up 1.7%.</font>&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316160-coupa-software-beats-0_06-beats-revenue\" target=\"_blank\">Coupa Software beats by $0.06, beats on revenue</a> (Dec. 4)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316170-coupa-software-minus-3_3-percent-despite-q3-beats-upside-guidance\" target=\"_blank\">Coupa Software -3.3% despite Q3 beats, upside guidance</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316399\" data-linked=\"Barclays comments on Coupa Software&#39;s earnings report\" data-tweet=\"$COUP - Barclays comments on Coupa Software&#39;s earnings report https://seekingalpha.com/news/3316399-barclays-comments-on-coupa-softwares-earnings-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3316399-barclays-comments-on-coupa-softwares-earnings-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:54 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316397\" data-ts=\"1512495686\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316397-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+101%</font>. <a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/CLIR' title='ClearSign Combustion Corp.'>CLIR</a> <font color='green'>+28%</font>. <a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/GRAM-OLD' title='Graa y Montero'>GRAM-OLD</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NES' title='Nuverra Environmental Solutions, Inc.'>OTC:NES</a> <font color='green'>+13%</font>.</li><li><b>Losers:&nbsp;</b><a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/PXS' title='Pyxis Tankers Inc.'>PXS</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/TRHC' title='Tabula Rasa HealthCare'>TRHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/RARX' title='Ra Pharmaceuticals'>RARX</a>&nbsp;<font color='red'>-11%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316397\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$SNCA $RVNC $CLIR - Midday Gainers / Losers https://seekingalpha.com/news/3316397-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3316397-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316394\" data-ts=\"1512494669\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMOT\" target=\"_blank\">AMOT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316394-alied-motion-technologies-announces-65m-award\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alied Motion Technologies announces $65M award</a></h4><ul><li>        Alied Motion Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/AMOT' title='Allied Motion Technologies, Inc.'>AMOT</a>) <a href=\"https://seekingalpha.com/pr/17017970-allied-motion-receives-additional-65-million-award-vehicle-market-solution\" target=\"_blank\">receives</a> a $65M award to provide solutions for the company&rsquo;s Vehicle market in Asia and Europe</li><li>                  Revenue for the application will ramp up in 2021 and mostly complete by 2028.    </li><li>                  Alied Motion previously announced a $90M award for the Vehicle market.    </li><li>               The new award brings this year&rsquo;s total $155M and the seven-year average to $22.1M per year.&nbsp;</li><li>Alied Motion Technologies shares are&nbsp;<font color='green'>up 1.9%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306980-allied-motion-technologies-beats-0_06-beats-revenue\" target=\"_blank\">Allied Motion Technologies beats by $0.06, beats on revenue</a> (Nov. 1)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3306820-allied-motion-technologies-declares-0_025-dividend\" target=\"_blank\">Allied Motion Technologies declares $0.025 dividend</a> (Nov. 1)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316394\" data-linked=\"Alied Motion Technologies announces $65M award\" data-tweet=\"$AMOT - Alied Motion Technologies announces $65M award https://seekingalpha.com/news/3316394-alied-motion-technologies-announces-65m-award?source=tweet\" data-url=\"https://seekingalpha.com/news/3316394-alied-motion-technologies-announces-65m-award\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:24 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316393\" data-ts=\"1512494047\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSNI\" target=\"_blank\">SSNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316393-itron-commences-300m-senior-note-offering-clears-antitrust-review\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Itron commences $300M senior note offering, clears antitrust review</a></h4><ul><li>        Itron<b> (</b>ITRI) <a href=\"https://seekingalpha.com/pr/17018232-itron-inc-announces-proposed-offering-300-million-senior-notes-due-2025\" target=\"_blank\">announces</a> the commencement of a $300M private offering of senior notes due 2025.</li><li>               The offering is part of the financing for the acquisition of Silver Spring Networks (NYSE:<a href='https://seekingalpha.com/symbol/SSNI' title='Silver Spring Networks'>SSNI</a>) and the following merger.&nbsp;</li><li>               Itron and Silver Springs also<a href=\"https://seekingalpha.com/pr/17018164-itron-acquisition-silver-spring-networks-clears-antitrust-review\" target=\"_blank\"> report</a> that the acquisition has cleared antitrust review in the U.S. The companies expect the deal to close early next year.&nbsp; &nbsp;</li><li>               Itron shares are&nbsp;<font color='green'>up 1.4%</font>.&nbsp;</li><li>               Silver Springs shares are&nbsp;<font color='green'>up 1.1%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3296334-canaccord-genuity-downgrades-itron-silver-spring-purchase\" target=\"_blank\">Canaccord Genuity downgrades Itron on Silver Spring purchase</a> (Sept. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316393\" data-linked=\"Itron commences $300M senior note offering, clears antitrust review\" data-tweet=\"$SSNI - Itron commences $300M senior note offering, clears antitrust review https://seekingalpha.com/news/3316393-itron-commences-300m-senior-note-offering-clears-antitrust-review?source=tweet\" data-url=\"https://seekingalpha.com/news/3316393-itron-commences-300m-senior-note-offering-clears-antitrust-review\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316392\" data-ts=\"1512493505\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SFS\" target=\"_blank\">SFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316392-jittery-trading-on-smart-final-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jittery trading on Smart &amp; Final Stores</a></h4><ul><li>Smart &amp; Final Stores (<a href='https://seekingalpha.com/symbol/SFS' title='Smart & Final Stores'>SFS</a> <font color='red'>-6.8%</font>) tracks lower after JPMorgan issues a cautious outlook on the grocery store operator.</li><li>The firm expects S&amp;F to face increased competition in California and points to a higher cost structure due to the Haggen acquisition. Naturally, the threat of Amazon is added to the mix by JP.</li><li>Shares are rated at Neutral and assigned a price target of $9.</li><li>Sources: CNBC and Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3316392\" data-linked=\"Jittery trading on Smart &amp; Final Stores\" data-tweet=\"$SFS - Jittery trading on Smart &amp; Final Stores https://seekingalpha.com/news/3316392-jittery-trading-on-smart-final-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3316392-jittery-trading-on-smart-final-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316391\" data-ts=\"1512493417\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUBS\" target=\"_blank\">HUBS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316391-hubspot-down-after-citron-research-report\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HubSpot down after Citron Research report</a></h4><ul><li>        HubSpot (NYSE:<a href='https://seekingalpha.com/symbol/HUBS' title='HubSpot, Inc.'>HUBS</a>) has a rough morning as <a href=\"https://twitter.com/CitronResearch/status/938080406699569152\" target=\"_blank\">Citron Research</a> releases a report on the company.</li><li>               Citron sees HubSpot shares dropping to $50 soon and to $25 in the long-term due to the fundamentals.&nbsp;</li><li>               Citron&rsquo;s Andrew Left will appear on Bloomberg Markets TV at 2:15 EST today to talk about the HubSpot report so expect more volatility later in the day.&nbsp;</li><li>               HubSpot shares are&nbsp;<font color='red'>down 1.7%</font>.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3316391\" data-linked=\"HubSpot down after Citron Research report\" data-tweet=\"$HUBS - HubSpot down after Citron Research report https://seekingalpha.com/news/3316391-hubspot-down-after-citron-research-report?source=tweet\" data-url=\"https://seekingalpha.com/news/3316391-hubspot-down-after-citron-research-report\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316389\" data-ts=\"1512493301\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316389-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/SYPR' title='Sypris Solutions, Inc.'>SYPR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/BETR' title='Amplify Snack Brands'>BETR</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/YGYI' title='Youngevity International, Inc.'>YGYI</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/CELH' title='Celsius Holdings, Inc.'>CELH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/TIS' title='Orchids Paper Products Company'>TIS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MAT' title='Mattel, Inc.'>MAT</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/KBSF' title='KBS Fashion Group Limited'>KBSF</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/ROX' title='Castle Brands Inc'>ROX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316389\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$GIII $SYPR $BETR-OLD - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3316389-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3316389-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316384\" data-ts=\"1512492288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316384-biocept-nabs-u-s-patent-covering-switch-blocker-technology-shares-ahead-13\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept nabs U.S. patent covering &quot;switch-blocker&quot; technology; shares ahead 13%</a></h4><ul><li>The USPTO <a href=\"https://seekingalpha.com/pr/17018229-first-u-s-patent-issued-biocepts-target-selector-oncogene-mutation-enrichment-detection\" target=\"_blank\">issues </a>U.S. Patent No. 9,834,817 to Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+12.5%</font>) covering methods of detecting nucleic acid sequence variants which it says encompasses its proprietary \"switch-blocker\" technology, designed to improve oncogene detection rates.</li><li>The '817 patent applies to a broad range of molecular diagnostic platforms, including digital PCR, real-time PCR, Sanger sequencing, next-gen sequencing, arrays, mass spectrometry and capillary detection systems.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316384\" data-linked=\"Biocept nabs U.S. patent covering &quot;switch-blocker&quot; technology; shares ahead 13%\" data-tweet=\"$BIOC - Biocept nabs U.S. patent covering &quot;switch-blocker&quot; technology; shares ahead 13% https://seekingalpha.com/news/3316384-biocept-nabs-u-s-patent-covering-switch-blocker-technology-shares-ahead-13?source=tweet\" data-url=\"https://seekingalpha.com/news/3316384-biocept-nabs-u-s-patent-covering-switch-blocker-technology-shares-ahead-13\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316385\" data-ts=\"1512492288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDS\" target=\"_blank\">FDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316385-northcoast-downgrades-factset-research-systems\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northcoast downgrades FactSet Research Systems</a></h4><ul><li>        Northcoast <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171205080302FDS\" target=\"_blank\">downgrades</a> FactSet Research Systems (NYSE:<a href='https://seekingalpha.com/symbol/FDS' title='FactSet Research Systems Inc.'>FDS</a>) from Buy to Neutral.</li><li>               Latest analyst recommendations (via <a href=\"https://markets.ft.com/data/equities/tearsheet/forecasts?s=FDS:NYQ\" target=\"_blank\">FT</a>): 1 Buy, 1 Outperform, 12 Hold, 2 Underperform, and 1 Sell.&nbsp;</li><li>               Median price target: $176.&nbsp;</li><li>                  FactSet shares are&nbsp;<font color='red'>down 1.5%</font>.    &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3316385\" data-linked=\"Northcoast downgrades FactSet Research Systems\" data-tweet=\"$FDS - Northcoast downgrades FactSet Research Systems https://seekingalpha.com/news/3316385-northcoast-downgrades-factset-research-systems?source=tweet\" data-url=\"https://seekingalpha.com/news/3316385-northcoast-downgrades-factset-research-systems\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316383\" data-ts=\"1512492044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316383-windstreamminus-6_8-after-consent-solicitation-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream -6.8% after consent solicitation update</a></h4><ul>   <li>Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='red'>down 6.8%</font> after the <a href=\"https://seekingalpha.com/pr/17018519-windstream-announces-results-consent-solicitations\" target=\"_blank\">latest update</a> on long-running consent solicitations on its senior debt -- moves to waive alleged defaults tied to the spin-off of Uniti Group (<a href=\"http://seekingalpha.com/symbol/UNIT\" target=\"_blank\">UNIT</a> <font color='green'>+0.4%</font>).</li>    <li>With an expiration date passing last night, the company says it's received consents from holders representing a majority of outstanding principal on 7.75% senior notes due 2021 and 7.5% senior notes due 2022.</li>    <li>\"The company has now received waivers and consents with respect to all series of the company&rsquo;s previously outstanding senior notes relating to alleged defaults with respect to the spin-off,\" Windstream says. \"Holders of over 90% of the outstanding aggregate principal amount of the company&rsquo;s notes delivered waivers and consents in the consent solicitations.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3315262-windstream-cfo-confident-default-face-aurelius\" target=\"_blank\">Windstream CFO confident about default face-off with Aurelius</a> (Nov. 29 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3314802-windstream-minus-2_5-percent-launches-latest-effort-waive-alleged-default\" target=\"_blank\">Windstream -2.5% as it launches latest effort to waive alleged default</a> (Nov. 28 2017)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316383\" data-linked=\"Windstream -6.8% after consent solicitation update\" data-tweet=\"$WIN $WINMQ $UNIT - Windstream -6.8% after consent solicitation update https://seekingalpha.com/news/3316383-windstreamminus-6_8-after-consent-solicitation-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3316383-windstreamminus-6_8-after-consent-solicitation-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>331&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316380\" data-ts=\"1512491771\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LXFT\" target=\"_blank\">LXFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316380-pivotal-research-initiates-luxoft-epam\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pivotal Research initiates Luxoft, EPAM</a></h4><ul><li>        Pivotal Research <a href=\"http://www.briefing.com/DisplayArticle/ArticlePopup.aspx?ArticleId=IN20171205060213EPAM\" target=\"_blank\">initiates</a> coverage on Luxoft Holding (NYSE:<a href='https://seekingalpha.com/symbol/LXFT' title='Luxoft Holding Inc'>LXFT</a>) with a Buy rating and $70 price target.</li><li>                  The firm also initiates EPAM Systems (NYSE:<a href='https://seekingalpha.com/symbol/EPAM' title='EPAM Systems'>EPAM</a>) at Buy with a $120 price target.    </li><li>               Pivotal calls EPAM a market leader with excellent and consistent results and considers Luxoft a turnaround play with more risk and the chance for greater reward.&nbsp;</li><li>                  Valuations: EPAM shares trading at 23x 2018 estimates and Luxoft at 14.5x CY18 estimates, which represents an almost 40% discount. &nbsp;&nbsp;   </li><li>                  Luxoft shares are&nbsp;<font color='green'>up 2.4%</font>.    </li><li>               EPAM shares are&nbsp;<font color='green'>up 1.2%</font>. &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3316380\" data-linked=\"Pivotal Research initiates Luxoft, EPAM\" data-tweet=\"$LXFT $LXFT $EPAM - Pivotal Research initiates Luxoft, EPAM https://seekingalpha.com/news/3316380-pivotal-research-initiates-luxoft-epam?source=tweet\" data-url=\"https://seekingalpha.com/news/3316380-pivotal-research-initiates-luxoft-epam\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316367\" data-ts=\"1512489904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CUR\" target=\"_blank\">CUR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316367-neuralstems-lead-candidate-nsiminus-189-shows-potential-efficacy-in-mdd-40-mg-dose-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neuralstem&#39;s lead candidate NSI-189 shows potential efficacy in MDD at 40 mg dose; shares ahead 67%</a></h4><ul><li>Thinly traded nano cap Neuralstem (<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+67%</font>) jumps on a whopping 55x surge in volume in response to <a href=\"https://seekingalpha.com/pr/17018029-neuralstem-presents-positive-updated-data-phase-2-study-nsiminus-189-major-depressive\" target=\"_blank\">new data</a> on lead candidate NSI-189 in major depressive disorder &#40;MDD&#41;. The results were presented at the American College of Neuropsychopharmacology Annual Meeting in Palm Springs, CA.</li><li>Patients receiving the 40 mg dose experienced statistically significant improvements in MDD symptoms as measured by scales called SDQ and CPFQ. There was also a statistically greater reduction in scores of another metric called QIDS-SR versus placebo in Stage 2 of the study.</li><li>The 80 mg dose failed to beat placebo.</li><li>The company intends to meet with the FDA in H1 2018 to discuss the results and a regulatory path to approval. It also plans to submit the data for publication.</li><li>The company says small molecule <a href=\"https://www.neuralstem.com/pipeline/ns-189\" target=\"_blank\">NSI-189</a>, a benzylpiperazine-aminopyridine, stimulates neurogenesis, synaptogenesis and increases hippocampal volume, all of which play a role in reversing depression, enhancing cognition and promoting the growth of new nerve tissue.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3280950-neuralstems-nsiminus-189-flunks-mid-stage-study-mdd-shares-plummet-61-percent-premarket\" target=\"_blank\">Neuralstem's NSI-189 flunks mid-stage study in MDD; shares plummet 61% premarket</a> (July 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316367\" data-linked=\"Neuralstem&#39;s lead candidate NSI-189 shows potential efficacy in MDD at 40 mg dose; shares ahead 67%\" data-tweet=\"$CUR $SNCA - Neuralstem&#39;s lead candidate NSI-189 shows potential efficacy in MDD at 40 mg dose; shares ahead 67% https://seekingalpha.com/news/3316367-neuralstems-lead-candidate-nsiminus-189-shows-potential-efficacy-in-mdd-40-mg-dose-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3316367-neuralstems-lead-candidate-nsiminus-189-shows-potential-efficacy-in-mdd-40-mg-dose-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316349\" data-ts=\"1512489755\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316349-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+70%</font>. <a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/AKTX' title='Akari Therapeutics Plc'>AKTX</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='red'>-35%</font>. <a href='https://seekingalpha.com/symbol/SNSS' title='Sunesis Pharmaceuticals, Inc.'>SNSS</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/HRTX' title='Heron Therapeutics, Inc.'>HRTX</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/FCSC' title='Fibrocell Science, Inc.'>FCSC</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316349\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$SNCA $RVNC $MBRX - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3316349-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3316349-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316370\" data-ts=\"1512489573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316370-petrobras-signs-5b-financing-deal-china-development-bank\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Petrobras signs $5B financing deal with China Development Bank</a></h4><ul>     <li>Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+1.7%</font>) says it signed a deal with China Development Bank for <a href=\"https://uk.reuters.com/article/petrobrs-asia-deals/update-1-petrobras-inks-5-bln-financing-deal-with-china-development-bank-idUKL1N1O50I3\" target=\"_blank\">$5M in financing</a> through 2027.</li>     <li>The Brazilian company says half the loan will be disbursed this month and the rest in January, when it will pay the remaining $2.8B it owes to the Chinese bank on a 2009 loan.</li>     <li>PBR also says it signed a contract with Unipec Asia Co. for the preferential supply of 100K boe/day for 10 years.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316370\" data-linked=\"Petrobras signs $5B financing deal with China Development Bank\" data-tweet=\"$PBR - Petrobras signs $5B financing deal with China Development Bank https://seekingalpha.com/news/3316370-petrobras-signs-5b-financing-deal-china-development-bank?source=tweet\" data-url=\"https://seekingalpha.com/news/3316370-petrobras-signs-5b-financing-deal-china-development-bank\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316365\" data-ts=\"1512488842\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AOBC\" target=\"_blank\">AOBC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316365-gun-stocks-volatile-ahead-of-key-house-vote\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gun stocks volatile ahead of key House vote</a></h4><ul><li>Gun stocks are on watch today ahead of a House <a href=\"https://www.theatlantic.com/politics/archive/2017/12/republican-house-vote-concealed-carry-gun-background-checks/547454/\" target=\"_blank\">vote</a> on a concealed carry bill.</li><li>The bipartisan bill initially addressed tightening up some laws on background checks, but now also includes opening up rules on carrying concealed guns over state lines.</li><li>Related stocks: American Outdoor Brands (<a href='https://seekingalpha.com/symbol/AOBC' title='American Outdoor Brands Corporation'>AOBC</a> <font color='red'>-3.6%</font>), Sturm Ruger (<a href='https://seekingalpha.com/symbol/RGR' title='Sturm, Ruger & Company Inc.'>RGR</a> <font color='red'>-2.3%</font>), Vista Outdoor (<a href='https://seekingalpha.com/symbol/VSTO' title='Vista Outdoor'>VSTO</a> <font color='red'>-3%</font>) and Sportsman's Warehouse Holdings (<a href='https://seekingalpha.com/symbol/SPWH' title='Sportsman&#39;s Warehouse Holdings, Inc.'>SPWH</a> <font color='red'>-3.7%</font>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3316365\" data-linked=\"Gun stocks volatile ahead of key House vote\" data-tweet=\"$AOBC $AOBC $RGR - Gun stocks volatile ahead of key House vote https://seekingalpha.com/news/3316365-gun-stocks-volatile-ahead-of-key-house-vote?source=tweet\" data-url=\"https://seekingalpha.com/news/3316365-gun-stocks-volatile-ahead-of-key-house-vote\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316364\" data-ts=\"1512488717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSG\" target=\"_blank\">MSG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316364-madison-square-gardenminus-2_7-morgan-stanley-backs-off-to-equal-weight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Madison Square Garden -2.7% as Morgan Stanley backs off to Equal Weight</a></h4><ul>   <li>Madison Square Garden (NASDAQ:<a href='https://seekingalpha.com/symbol/MSG' title='The Madison Square Garden Company'>MSG</a>) is <font color='red'>off 2.7%</font>, adding to premarket losses, after a cut to Equal Weight by Morgan Stanley.</li>    <li>The firm had rated MSG Overweight based on a heavy discount to net asset value -- a gap that's narrowed after performance this year (shares are <font color='green'>up 24%</font> in 2017).</li>    <li>But investors may be disappointed if the company decides on a risky long-term path for venue expansion, rather than opting for asset sales, buybacks or even going private, says Benjamin Swinburne. (h/t Bloomberg)</li>    <li>He has an unchanged price target of $245, implying 15% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316364\" data-linked=\"Madison Square Garden -2.7% as Morgan Stanley backs off to Equal Weight\" data-tweet=\"$MSG - Madison Square Garden -2.7% as Morgan Stanley backs off to Equal Weight https://seekingalpha.com/news/3316364-madison-square-gardenminus-2_7-morgan-stanley-backs-off-to-equal-weight?source=tweet\" data-url=\"https://seekingalpha.com/news/3316364-madison-square-gardenminus-2_7-morgan-stanley-backs-off-to-equal-weight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316362\" data-ts=\"1512488073\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZYME\" target=\"_blank\">ZYME</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316362-zymeworks-lead-candidate-shows-positive-action-in-early-stage-study-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zymeworks&#39; lead candidate shows positive action in early-stage study; shares up 1%</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/17017869-zymeworks-presents-results-completed-dose-escalation-portion-ongoing-phase-1-study-zw25-san\" target=\"_blank\">Preliminary results</a> from a Phase 1 dose-escalation study evaluating Zymeworks' (<a href='https://seekingalpha.com/symbol/ZYME' title='Zymeworks'>ZYME</a> <font color='green'>+1%</font>) lead candidate ZW25 in patients with HER2-expressing cancers showed a treatment effect. The data will be presented on Friday, December 8 at the San Antonio Breast Cancer Symposium.</li><li>A total of 22 patients are enrolled, 11 with breast cancer, eight with gastric, gastroesophageal junction or esophageal &#40;GE&#41;&nbsp;cancer and three with other HER2-expressing cancers.</li><li>The partial response rate was 27% (n=6/22) across all dose groups. In breast cancer patients who received a median of six prior lines of HER2-targeted therapy, the partial response rate was 56% (n=5/9) in those with measurable disease with 89% (n=8/9) showing decreases in target lesions.</li><li>Three HER2-high GE cancer patients with measurable disease showed tumor shrinkage, including one partial responder and one with stable disease after six months.</li><li>79% (n=11/14) of breast and GE cancer patients with measurable disease experienced decreases in target lesions.</li><li>On the safety front, ZW25 was well-tolerated with all adverse events (AEs)&nbsp;considered mild or moderate. The most frequent AEs were diarrhea, infusion reactions and nausea.</li><li>Enrollment is underway in the second part of the trial evaluating a regimen of 20 mg/kg of ZW25 every other week in four expansion cohorts in HER2-high cancers.</li><li><a href=\"https://www.zymeworks.com/our-pipeline/zw25\" target=\"_blank\">ZW25 </a>is a bispecific antibody that can simultaneously bind to two non-overlapping epitopes of HER2, thereby increasing binding and removal of HER2 protein from the cell surface and boosting efficacy.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>11%</font>&nbsp;on modestly higher volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316362\" data-linked=\"Zymeworks&#39; lead candidate shows positive action in early-stage study; shares up 1%\" data-tweet=\"$ZYME - Zymeworks&#39; lead candidate shows positive action in early-stage study; shares up 1% https://seekingalpha.com/news/3316362-zymeworks-lead-candidate-shows-positive-action-in-early-stage-study-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3316362-zymeworks-lead-candidate-shows-positive-action-in-early-stage-study-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316358\" data-ts=\"1512486704\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIX\" target=\"_blank\">EIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316358-edisonminus-10-out-of-control-southern-california-fire-spreads-quickly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Edison -10% as out of control southern California fire spreads quickly</a></h4><ul>     <li>Edison International (<a href='https://seekingalpha.com/symbol/EIX' title='Edison International'>EIX</a> <font color='red'>-10.5%</font>) plunges ~10% in early trading as a <a href=\"https://twitter.com/SCE/status/937950829226659840\" target=\"_blank\">California brush fire</a> leaves 180K customers in Ventura County and another 83K in the Santa Barbara area without power.</li>     <li>Named the <a href=\"https://www.washingtonpost.com/news/morning-mix/wp/2017/12/05/out-of-control-southern-california-brush-fire-grows-from-50-to-25000-acres-in-7-hours/?utm_term=.1f6b3b47f214\" target=\"_blank\">Thomas Fire</a>, it began in a canyon near Santa Paula, about 65 miles northwest of downtown Los Angeles, and spread from 50 acres to ~31K acres in a matter of hours, forcing thousands of residents to flee.</li><li>&ldquo;The prospects for containment are not good,&rdquo; says the Ventura County fire chief.</li><li>PG&amp;E (<a href='https://seekingalpha.com/symbol/PCG' title='PG&E Corporation'>PCG</a> <font color='red'>-1.3%</font>), which suffered from the recent string of fires in the northern part of the state, also trades lower.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316358\" data-linked=\"Edison -10% as out of control southern California fire spreads quickly\" data-tweet=\"$EIX $EIX $PCG - Edison -10% as out of control southern California fire spreads quickly https://seekingalpha.com/news/3316358-edisonminus-10-out-of-control-southern-california-fire-spreads-quickly?source=tweet\" data-url=\"https://seekingalpha.com/news/3316358-edisonminus-10-out-of-control-southern-california-fire-spreads-quickly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316357\" data-ts=\"1512486468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316357-fashion-missteps-clip-ascena-retail\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fashion missteps clip Ascena Retail</a></h4><ul><li>Shares of Ascena Retail Group (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-21.6%</font>) are down sharply after the retailer sets FQ2 guidance below expectations.</li><li>Amid a strategy reset, the retail chain expects comparable sales to fall 4% to 6% next quarter.</li><li>Ascena disclosed that it closed 36 stores in FQ1, and aims to close up to 667 stores over the next several years.</li><li>Ascena's results in FQ1 were impacted negatively by some \"fashion missteps\" in front of the crucial holiday period.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316154-ascena-retail-group-eps-revenue-line\" target=\"_blank\">Ascena Retail Group EPS and revenue in-line</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316357\" data-linked=\"Fashion missteps clip Ascena Retail\" data-tweet=\"$ASNA - Fashion missteps clip Ascena Retail https://seekingalpha.com/news/3316357-fashion-missteps-clip-ascena-retail?source=tweet\" data-url=\"https://seekingalpha.com/news/3316357-fashion-missteps-clip-ascena-retail\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316356\" data-ts=\"1512486421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316356-shire-teams-up-rani-therapeutics-to-develop-oral-factor-viii-therapy-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shire teams up with Rani Therapeutics to develop oral factor VIII therapy; shares up 1%</a></h4><ul><li>Shire plc (<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a> <font color='green'>+1%</font>) inks a <a href=\"https://seekingalpha.com/pr/17018036-shire-rani-therapeutics-enter-collaboration-evaluate-use-rani-pill-tm-technology-oral\" target=\"_blank\">collaboration agreement</a> with <a href=\"https://www.ranitherapeutics.com/\" target=\"_blank\">Rani Therapeutics</a> to explore the use of the latter's Rani Pill Technology for the oral delivery of factor VIII therapy for hemophilia A patients. Shire will have the exclusive option for a license to develop and commercialize the technology for the indication after feasibility studies are completed.</li><li>The <a href=\"https://www.ranitherapeutics.com/technology/\" target=\"_blank\">Rani Pill </a>enables the delivery of large molecules without exposing the drugs to digestive enzymes. Once ingested, the capsule delivers the payload via an injection into the small intestine. The injection should be pain-free due to the absence of sharp pain receptors in that part of the digestive tract.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316356\" data-linked=\"Shire teams up with Rani Therapeutics to develop oral factor VIII therapy; shares up 1%\" data-tweet=\"$SHPG - Shire teams up with Rani Therapeutics to develop oral factor VIII therapy; shares up 1% https://seekingalpha.com/news/3316356-shire-teams-up-rani-therapeutics-to-develop-oral-factor-viii-therapy-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3316356-shire-teams-up-rani-therapeutics-to-develop-oral-factor-viii-therapy-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316355\" data-ts=\"1512486054\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOX\" target=\"_blank\">FOX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316355-fox-jumps-on-cnbc-report-of-nearing-asset-sale-to-disney\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fox jumps on CNBC report of nearing asset sale to Disney</a></h4><ul>     <li>Shares in Twenty-First Century Fox (<a href='https://seekingalpha.com/symbol/FOX' title='Twenty-First Century Fox, Inc.'>FOX</a> <font color='green'>+3.6%</font>, <a href='https://seekingalpha.com/symbol/FOXA' title='Twenty-First Century Fox, Inc.'>FOXA</a> <font color='green'>+3.4%</font>) are jumping as CNBC's David Faber says the company's <a href=\"https://www.cnbc.com/2017/12/05/disney-and-fox-are-closing-in-on-deal-could-be-announced-next-week--sources.html\" target=\"_blank\">closing in on a deal</a> to sell assets to Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) that could be announced next week.</li>     <li>Disney is <font color='red'>off 1.3%</font> today.</li>     <li>The assets commonly known as being on the block -- Fox's TV and film studio assets, along with a stake in Sky (<a href='https://seekingalpha.com/symbol/SKYAY' title='Sky Plc ADR'>OTCPK:SKYAY</a>)&nbsp; and its share of Hulu -- are seen to have an enterprise value that could exceed $60B. In any deal, Fox would keep its news and sports operations along with its broadcast network.</li>  <li><b>Updated 10:04 a.m.:</b> The report suggests Disney is <a href=\"https://seekingalpha.com/news/3316151-report-disney-pole-position-major-fox-asset-purchase-stocks-rise\" target=\"_blank\">much further ahead than other rivals</a> linked to possible purchases of the assets: Comcast (<a href=\"http://seekingalpha.com/symbol/CMCSA\" target=\"_blank\">CMCSA</a> <font color='red'>-1.1%</font>), Verizon (<a href=\"http://seekingalpha.com/symbol/VZ\" target=\"_blank\">VZ</a> <font color='red'>-0.8%</font>), Sony (<a href=\"http://seekingalpha.com/symbol/SNE\" target=\"_blank\">SNE</a> <font color='green'>+0.2%</font>), and Amazon.com (<a href=\"http://seekingalpha.com/symbol/AMZN\" target=\"_blank\">AMZN</a> <font color='green'>+1.2%</font>).</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316355\" data-linked=\"Fox jumps on CNBC report of nearing asset sale to Disney\" data-tweet=\"$FOX $FOX $FOXA - Fox jumps on CNBC report of nearing asset sale to Disney https://seekingalpha.com/news/3316355-fox-jumps-on-cnbc-report-of-nearing-asset-sale-to-disney?source=tweet\" data-url=\"https://seekingalpha.com/news/3316355-fox-jumps-on-cnbc-report-of-nearing-asset-sale-to-disney\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:00 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316353\" data-ts=\"1512485846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDDY\" target=\"_blank\">GDDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316353-godaddy-prices-common-stock-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoDaddy prices common stock offering</a></h4><ul><li>        GoDaddy (NYSE:<a href='https://seekingalpha.com/symbol/GDDY' title='GoDaddy Inc.'>GDDY</a>) <a href=\"https://seekingalpha.com/pr/17018526-godaddy-inc-announces-pricing-proposed-sale-shares-common-stock\" target=\"_blank\">prices</a> its underwritten public offering of about 7.3M shares of common stock at $47.32 per share.</li><li>                  As announced yesterday, the shares come from selling stockholders and GoDaddy won&rsquo;t receive any proceeds from those shares. The company does have its own 50K share offering and will receive those proceeds. &nbsp;   </li><li>GoDaddy shares are&nbsp;<font color='green'>up 1.2%</font>.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316194-godaddy-announces-public-offering\" target=\"_blank\">GoDaddy announces public offering</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316353\" data-linked=\"GoDaddy prices common stock offering\" data-tweet=\"$GDDY - GoDaddy prices common stock offering https://seekingalpha.com/news/3316353-godaddy-prices-common-stock-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3316353-godaddy-prices-common-stock-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:57 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316351\" data-ts=\"1512485428\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNED\" target=\"_blank\">BNED</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316351-post-earnings-rip-for-barnes-noble-education\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Post-earnings rip for Barnes &amp; Noble Education</a></h4><ul>     <li>Barnes &amp; Noble Education (<a href='https://seekingalpha.com/symbol/BNED' title='Barnes & Noble Education, Inc'>BNED</a> <font color='green'>+21.6%</font>) spikes after the company crushes <a href=\"https://seekingalpha.com/pr/17018306-barnes-and-noble-education-reports-second-quarter-2018-financial-results\" target=\"_blank\">FQ2</a> estimates.</li>     <li>Adjusted EBITDA almost doubled to $102M during the quarter.</li><li>\"Our substantially increased financial results in the second quarter reflect the contributions of our recent acquisitions of MBS and Student Brands. While both of these teams continue to perform financially, we are even more encouraged by their respective potential contributions to BNED&rsquo;s longer term competitive position,&rdquo; says CEO Michael Huseby.</li>          <li>The company reaffirms FY18 guidance for $2.25B to $2.35B in revenue. The mark is above the consensus estimate of $2.18B.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316314-barnes-and-noble-education-beats-0_12-beats-revenue\" target=\"_blank\">Barnes &amp; Noble Education beats by $0.12, beats on revenue</a> (Dec. 5)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316351\" data-linked=\"Post-earnings rip for Barnes &amp; Noble Education\" data-tweet=\"$BNED - Post-earnings rip for Barnes &amp; Noble Education https://seekingalpha.com/news/3316351-post-earnings-rip-for-barnes-noble-education?source=tweet\" data-url=\"https://seekingalpha.com/news/3316351-post-earnings-rip-for-barnes-noble-education\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316348\" data-ts=\"1512485364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NEON\" target=\"_blank\">NEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316348-neonode-ceo-to-step-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Neonode CEO to step down</a></h4><ul><li>        Neonode (NASDAQ:<a href='https://seekingalpha.com/symbol/NEON' title='Neonode, Inc.'>NEON</a>) <a href=\"https://seekingalpha.com/pr/17018495-thomas-eriksson-resign-ceo-neonode\" target=\"_blank\">announces</a> that co-founder and CEO Thomas Eriksson will step down at the end of the year.</li><li>               Eriksson will take on other roles in Neonode and will remain on the board of directors.&nbsp;</li><li>               Investor and board member Andreas Bunge will step in as interim CEO. Bunge previously served as the CEO for Spago Nanomedical and Accelerator Nordic AB. &nbsp;&nbsp;</li><li>Neonode shares are&nbsp;<font color='green'>up 1%</font>.&nbsp; &nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3310579-neonode-eps-line-misses-revenue\" target=\"_blank\">Neonode EPS in-line, misses on revenue</a> (Nov. 9)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316348\" data-linked=\"Neonode CEO to step down\" data-tweet=\"$NEON - Neonode CEO to step down https://seekingalpha.com/news/3316348-neonode-ceo-to-step-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3316348-neonode-ceo-to-step-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316342\" data-ts=\"1512484116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAND\" target=\"_blank\">BAND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316342-bandwidthplus-4_4-quiet-period-ends-handful-of-new-buy-ratings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bandwidth +4.4% as quiet period ends with handful of new Buy ratings</a></h4><ul>   <li>Bandwidth (NASDAQ:<a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth, Inc.'>BAND</a>) is <font color='green'>up 4.4%</font> premarket as the expiration of its quiet period brings initiations at the Buy level from a handful of bullish analysts.</li>    <li>Morgan Stanley says the comms firm is a \"rare value proposition\" that owns both its platform and the underlying network in an early-stage industry ripe for rapid growth. The market is discounting its value proposition especially with larger customers and valuation is below any of its comps.</li>    <li>MS has a price target of $28, implying 25.2% upside. A higher price target of $29 comes from KeyBanc, which has also started the stock at Overweight and says the Communications Platform-as-a-Service industry could grow more than 20% in the second half of 2018.</li>    <li>Baird also notes Bandwidth's focus on bigger customers and says voice calling from smart speakers (notably Amazon Echo and Google Home) can drive a significant growth opportunity. It's rating the stock Outperform with a $28 target.</li>    <li>Also Buy-rating: Canaccord with a price target of $28, and JMP Securities with a Street-high target of $36 (implying 61% upside).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316342\" data-linked=\"Bandwidth +4.4% as quiet period ends with handful of new Buy ratings\" data-tweet=\"$BAND - Bandwidth +4.4% as quiet period ends with handful of new Buy ratings https://seekingalpha.com/news/3316342-bandwidthplus-4_4-quiet-period-ends-handful-of-new-buy-ratings?source=tweet\" data-url=\"https://seekingalpha.com/news/3316342-bandwidthplus-4_4-quiet-period-ends-handful-of-new-buy-ratings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316341\" data-ts=\"1512484086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HRTX\" target=\"_blank\">HRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316341-heron-prices-equity-offering-shares-down-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Heron prices equity offering; shares down 10% premarket</a></h4><ul><li>Heron Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/HRTX' title='Heron Therapeutics, Inc.'>HRTX</a>) is down&nbsp;<font color='red'>10%</font>&nbsp;premarket on increased volume in response to <a href=\"https://seekingalpha.com/pr/17018476-heron-therapeutics-announces-pricing-public-offering-common-stock\" target=\"_blank\">at-the-market pricing</a> of its $150M public offering of common stock.</li><li>Underwriters over-allotment is an additional $22.5M of stock. Closing date is December 7.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316341\" data-linked=\"Heron prices equity offering; shares down 10% premarket\" data-tweet=\"$HRTX - Heron prices equity offering; shares down 10% premarket https://seekingalpha.com/news/3316341-heron-prices-equity-offering-shares-down-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316341-heron-prices-equity-offering-shares-down-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316340\" data-ts=\"1512483877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316340-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='green'>+36%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3316291-fda-signs-early-stage-study-moleculins-wp1066-brain-tumors-shares-36-percent-premarket\" target=\"_blank\">signs off</a> on early-stage study of Moleculin's WP1066 in brain tumors.</li>     <li><a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a> <font color='green'>+31%</font>&nbsp;as RT002 <a href=\"https://seekingalpha.com/news/3316307-revances-rt002-successful-late-stage-studies-shares-ahead-25-percent-premarket\" target=\"_blank\">successful</a> in late-stage studies.</li>     <li><a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='green'>+23%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17018029-neuralstem-presents-positive-updated-data-phase-2-study-nsiminus-189-major-depressive\" target=\"_blank\">positive updated</a> data from phase 2 Study of NSI-189.</li>     <li><a href='https://seekingalpha.com/symbol/DGLY' title='Digital Ally, Inc.'>DGLY</a> <font color='green'>+16%</font>&nbsp;on awarded <a href=\"https://seekingalpha.com/pr/17018200-digital-ally-awarded-patent-wirelessly-conducted-electroshock-weapon\" target=\"_blank\">patent&nbsp;</a> on the&nbsp;revolutionary wirelessly conducted and controlled electroshock weapon.</li>     <li><a href='https://seekingalpha.com/symbol/LE' title='Lands&#39; End, Inc.'>LE</a> <font color='green'>+13%</font>. on Q3 <a href=\"https://seekingalpha.com/news/3316261-lands-end-beats-0_05-beats-revenue\" target=\"_blank\">earning</a>.</li>     <li><a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a> <font color='green'>+12%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316267-g-iii-apparel-beats-0_13-misses-revenue\" target=\"_blank\">earning</a>.</li>     <li>DEPO <font color='green'>+12%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316184-collegium-nabs-u-s-rights-depomeds-nucynta\" target=\"_blank\">agreement</a> with Collegium (NASDAQ:<a href='https://seekingalpha.com/symbol/COLL' title='Collegium Pharmaceutical'>COLL</a>).</li>     <li><a href='https://seekingalpha.com/symbol/RGC' title='Regal Entertainment Group'>RGC</a> <font color='green'>+9%</font>&nbsp;on being <a href=\"https://seekingalpha.com/news/3316248-cineworld-buy-regal-3_6b\" target=\"_blank\">acquired</a> by Cineworld.</li>     <li><a href='https://seekingalpha.com/symbol/MYO' title='Myomo, Inc.'>MYO</a> <font color='green'>+8%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/HDS' title='HD Supply'>HDS</a> <font color='green'>+7%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3316243-hd-supply-beats-0_04-beats-revenue\" target=\"_blank\">earning</a>.</li>     <li><a href='https://seekingalpha.com/symbol/GLBS' title='Globus Maritime Ltd.'>GLBS</a> <font color='green'>+6%</font>.</li>     <li><a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a> <font color='green'>+5%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316316-barclays-upgrades-snap-raises-price-target\" target=\"_blank\">positive</a> upgrade from Barclays.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316340\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$MBRX $RVNC $SNCA - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3316340-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3316340-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316339\" data-ts=\"1512483728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316339-vale-upgraded-credit-suisse-preferred-stock-for-commodity-upcycle\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vale upgraded at Credit Suisse as preferred stock for commodity upcycle</a></h4><ul>     <li>Vale (NYSE:<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a>)&nbsp;<font color='green'>+1.6%</font> premarket after Credit Suisse <a href=\"https://www.streetinsider.com/Analyst+PT+Change/Credit+Suisse+Upgrades+Vale+S.A.+%28VALE%29+to+Outperform/13567641.html\" target=\"_blank\">upgrades</a> shares to Outperform from Neutral and raises its price target to $15 from $9.50, citing positive structural changes in China and the company's highly qualified team in place to deliver a deleveraging strategy.</li>     <li>Credit Suisse says Vale is its preferred name for exposure to the current uphill commodity cycle, as the firm raises its iron ore forecast for 2018 to $67.20/ton and $62.50/ton for 2019, from a respective $55 and $48, as a combination of strong margins of steelmakers in China and high capacity  utilization of the steel industry in the country has caused an increase  in demand for high-grade ore.</li><li>The firm thinks Vale's focus on capital allocation, cost reduction and sales volume optimization should drive the stock to new highs.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316339\" data-linked=\"Vale upgraded at Credit Suisse as preferred stock for commodity upcycle\" data-tweet=\"$VALE - Vale upgraded at Credit Suisse as preferred stock for commodity upcycle https://seekingalpha.com/news/3316339-vale-upgraded-credit-suisse-preferred-stock-for-commodity-upcycle?source=tweet\" data-url=\"https://seekingalpha.com/news/3316339-vale-upgraded-credit-suisse-preferred-stock-for-commodity-upcycle\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316336\" data-ts=\"1512483131\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316336-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>&nbsp;<font color='red'>-47%</font>&nbsp;on mid-stage <a href=\"https://seekingalpha.com/news/3316327-galectin-46-percent-premarket-mid-stage-results-nash-candidate-gr-mdminus-02\" target=\"_blank\">results</a> of NASH candidate GR-MD-02.</li><li><a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a>&nbsp;<font color='red'>-20%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316154-ascena-retail-group-eps-revenue-line\" target=\"_blank\">Q1 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/HRTX' title='Heron Therapeutics, Inc.'>HRTX</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316171-heron-launches-stock-offering-shares-8-percent-hours\" target=\"_blank\">launching</a> stock offering.</li><li><a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>&nbsp;<font color='red'>-10%</font>&nbsp;after Cinemark <a href=\"https://seekingalpha.com/news/3316284-moviepass-owner-falls-cinemark-unveils-subscription-plan\" target=\"_blank\">launches</a> a monthly movie membership program.</li><li><a href='https://seekingalpha.com/symbol/ASTC' title='Astrotech Corporation'>ASTC</a> <font color='red'>-8%</font>.</li><li><a href='https://seekingalpha.com/symbol/TOL' title='Toll Brothers Inc.'>TOL</a>&nbsp;<font color='red'>-7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316239-toll-brothers-misses-0_02-misses-revenue\" target=\"_blank\">Q4 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3316283-francescas-misses-0_03-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316336\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$GALT $ASNA $DPW - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3316336-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3316336-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316334\" data-ts=\"1512482899\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DPW\" target=\"_blank\">DPW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316334-digital-powerminus-13-on-sminus-3-filing-after-soaring-91-yesterday\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Digital Power -13% on S-3 filing after soaring 91% yesterday</a></h4><ul>     <li>Digital Power (NYSEMKT:<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>) <font color='red'>-13.2%</font> premarket after filing for a <a href=\"https://www.streetinsider.com/SEC+Filings/Form+S-3+DIGITAL+POWER+CORP+/13566768.html\" target=\"_blank\">shelf offering</a> of nearly 2.3M common shares by selling stockholders.</li>     <li>Shares had soared 91% in yesterday's trade after saying it planned to launch \"a line of advanced technology power systems for <a href=\"https://seekingalpha.com/pr/17016628-dpw-s-subsidiary-coolisys-technologies-unveils-first-cryptocurrency-hardware\" target=\"_blank\">digital mining of cryptocurrencies</a>, including Bitcoin and the other top digital currencies worldwide.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316334\" data-linked=\"Digital Power -13% on S-3 filing after soaring 91% yesterday\" data-tweet=\"$DPW - Digital Power -13% on S-3 filing after soaring 91% yesterday https://seekingalpha.com/news/3316334-digital-powerminus-13-on-sminus-3-filing-after-soaring-91-yesterday?source=tweet\" data-url=\"https://seekingalpha.com/news/3316334-digital-powerminus-13-on-sminus-3-filing-after-soaring-91-yesterday\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316333\" data-ts=\"1512482790\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316333-allergan-under-modest-pressure-on-potential-encroachment-of-revance-on-botox-franchise-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan under modest pressure on potential encroachment of Revance on Botox franchise; shares down 2% premarket</a></h4><ul><li>Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) slips&nbsp;<font color='red'>2%</font>&nbsp;premarket on modest volume in apparent response to positive late-stage data on Revance Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) DaxibotulinimtoxinA for the treatment of frown lines. Revance's neuromodulator has a six-month duration of action, longer than&nbsp;<a href=\"https://www.botoxcosmetic.com/\" target=\"_blank\">BOTOX Cosmetic</a>'s three-to-four months.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316307-revances-rt002-successful-late-stage-studies-shares-ahead-25-percent-premarket\" target=\"_blank\">Revance's RT002 successful in late-stage studies; shares ahead 25% premarket</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316333\" data-linked=\"Allergan under modest pressure on potential encroachment of Revance on Botox franchise; shares down 2% premarket\" data-tweet=\"$AGN $AGN $RVNC - Allergan under modest pressure on potential encroachment of Revance on Botox franchise; shares down 2% premarket https://seekingalpha.com/news/3316333-allergan-under-modest-pressure-on-potential-encroachment-of-revance-on-botox-franchise-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3316333-allergan-under-modest-pressure-on-potential-encroachment-of-revance-on-botox-franchise-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:06 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316327\" data-ts=\"1512482231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316327-galectin-down-46-premarket-on-mid-stage-results-for-nash-candidate-gr-mdminus-02\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin down 46% premarket on mid-stage results for NASH candidate GR-MD-02</a></h4><ul><li>The premarket up move for Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) seems like a distant memory. Shares are down&nbsp;<font color='red'>46%&nbsp;</font>after it announced results from a mid-stage study of NASH candidate GR-MD-02. The study missed the primary endpoint but did show a statistically valid treatment effect in a subset of patients.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316321-galectins-gr-mdminus-02-shows-treatment-benefit-subset-nash-patients-mid-stage-study-shares\" target=\"_blank\">Galectin's GR-MD-02 shows treatment benefit in subset of NASH patients in mid-stage study; shares ahead 27% premarket</a> (Dec. 5)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316327\" data-linked=\"Galectin down 46% premarket on mid-stage results for NASH candidate GR-MD-02\" data-tweet=\"$GALT - Galectin down 46% premarket on mid-stage results for NASH candidate GR-MD-02 https://seekingalpha.com/news/3316327-galectin-down-46-premarket-on-mid-stage-results-for-nash-candidate-gr-mdminus-02?source=tweet\" data-url=\"https://seekingalpha.com/news/3316327-galectin-down-46-premarket-on-mid-stage-results-for-nash-candidate-gr-mdminus-02\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>36&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316326\" data-ts=\"1512482079\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TEUM\" target=\"_blank\">TEUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316326-pareteumplus-3_4-on-smart-city-deal-in-eastern-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pareteum +3.4% on Smart City deal in eastern Europe</a></h4><ul>   <li>Pareteum (NYSEMKT:<a href='https://seekingalpha.com/symbol/TEUM' title='Pareteum Corporation'>TEUM</a>) is <font color='green'>up 3.4%</font> premarket on heavy volume after <a href=\"https://seekingalpha.com/pr/17018249-major-eastern-european-capital-city-selects-pareteums-platform-manage-multi-million-dollar\" target=\"_blank\">announcing a deal</a> with an major eastern European capital city to extend into its Smart City technology.</li>    <li>It's an expansion of a $24M agreement that will add an incremental $8M in revenue over five years.</li>    <li>Smart City initiatives include clean air monitoring, first responder networks, smart grid, smart meters, energy management, location tracking and high bandwidth Internet, the company says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316326\" data-linked=\"Pareteum +3.4% on Smart City deal in eastern Europe\" data-tweet=\"$TEUM - Pareteum +3.4% on Smart City deal in eastern Europe https://seekingalpha.com/news/3316326-pareteumplus-3_4-on-smart-city-deal-in-eastern-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3316326-pareteumplus-3_4-on-smart-city-deal-in-eastern-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:54 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316321\" data-ts=\"1512481780\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GALT\" target=\"_blank\">GALT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316321-galectins-gr-mdminus-02-shows-treatment-benefit-in-subset-of-nash-patients-in-mid-stage-study\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Galectin&#39;s GR-MD-02 shows treatment benefit in subset of NASH patients in mid-stage study; shares ahead 27% premarket</a></h4><ul><li>Thinly traded nano cap Galectin Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a>) is up&nbsp;<font color='green'>27%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/17018252-galectin-therapeutics-announces-results-phase-2b-nash-cx-trial\" target=\"_blank\">announcement </a>of results from a Phase 2b clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02462967?term=gr-md-02&amp;rank=1\" target=\"_blank\">NASH-CX</a>, evaluating lead candidate GR-MD-02 in NASH cirrhosis patients with portal hypertension.</li><li>The study failed to achieve the primary endpoint of a statistically valid reduction in hepatic venous pressure gradient &#40;HVPG&#41; compared to placebo in all subjects.</li><li>In a subset (50%) of participants, those without <a href=\"https://my.clevelandclinic.org/health/articles/esophageal-varices\" target=\"_blank\">esophageal varices</a> (dilated veins in the esophagus due to the pressure from portal hypertension), showed a statistically significant improvement in HVPG versus placebo.</li><li>There were also statistically significant effects on improving hepatocyte ballooning (liver cell death) and reducing the development of new esophageal varices in patients without varices at baseline.</li><li>In terms of absolute reductions in HVPG from baseline, there was a statistically significant greater proportion of responders without varices compared to placebo.</li><li>The company intends to advance the program into Phase 3 development.</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>46%</font>&nbsp;premarket on resumption of trading.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316321\" data-linked=\"Galectin&#39;s GR-MD-02 shows treatment benefit in subset of NASH patients in mid-stage study; shares ahead 27% premarket\" data-tweet=\"$GALT - Galectin&#39;s GR-MD-02 shows treatment benefit in subset of NASH patients in mid-stage study; shares ahead 27% premarket https://seekingalpha.com/news/3316321-galectins-gr-mdminus-02-shows-treatment-benefit-in-subset-of-nash-patients-in-mid-stage-study?source=tweet\" data-url=\"https://seekingalpha.com/news/3316321-galectins-gr-mdminus-02-shows-treatment-benefit-in-subset-of-nash-patients-in-mid-stage-study\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316316\" data-ts=\"1512481056\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNAP\" target=\"_blank\">SNAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316316-barclays-upgrades-snap-raises-price-target\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays upgrades Snap, raises price target</a></h4><ul><li>        Barclays <a href=\"https://www.cnbc.com/2017/12/05/snap-shares-jump-after-barclays-says-turning-point-coming-in-2018.html\" target=\"_blank\">upgrades</a> Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) from Equal Weight to Overweight and raises its price target from $11 to $18.</li><li>               Analyst Ross Sandler steps off the sidelines on expectations that Snap will begin hitting or exceeding consensus revenue estimates as growth accelerates next year.&nbsp;</li><li>               Sandler says the &ldquo;pricing transition&rdquo; is in the late stage and Snap could benefit from a sentiment shift that sees the company coexisting with Facebook. &nbsp;&nbsp;</li><li>               Snap shares are&nbsp;<font color='green'>up 6%</font>&nbsp;premarket.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316212-facebook-targets-young-children-messenger-kids\" target=\"_blank\">Facebook targets young children with Messenger Kids</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316316\" data-linked=\"Barclays upgrades Snap, raises price target\" data-tweet=\"$SNAP - Barclays upgrades Snap, raises price target https://seekingalpha.com/news/3316316-barclays-upgrades-snap-raises-price-target?source=tweet\" data-url=\"https://seekingalpha.com/news/3316316-barclays-upgrades-snap-raises-price-target\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>35&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316308\" data-ts=\"1512480315\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNOA\" target=\"_blank\">SNOA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316308-fda-approved-sonomas-antimicrobial-claim-for-alevicyn-gel-products-for-management-of-atopic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA approved Sonoma&#39;s antimicrobial claim for Alevicyn gel products for management of atopic dermatitis</a></h4><ul><li>Sonoma Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SNOA' title='Sonoma Pharmaceuticals, Inc.'>SNOA</a>) <a href=\"https://seekingalpha.com/pr/17018037-sonoma-pharmaceuticals-announces-second-fda-approval-add-antimicrobial-language-alevicyn-gel\" target=\"_blank\">announces</a> that the FDA has approved an expanded antimicrobial claim for the company&rsquo;s key dermatology gel product, Alevicyn SG Antipruritic Spray Gel, reflecting the product&rsquo;s widening clinical utility.</li>   <li>Jeff Day, President of dermatology division, IntraDerm Pharmaceuticals says,&nbsp;&ldquo;With this second FDA approval now in hand, we&rsquo;re pleased that both the Alevicyn Dermal Spray solution and gel products for the management of atopic dermatitis or eczema have expanded claims to include antimicrobial language and data demonstrating effectiveness against clinically relevant organisms.&rdquo;</li>  <li>The first regulatory clearance to expand label language was issued in November by the FDA for the Alevicyn Dermal Spray.</li><li>Shares are up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3316308\" data-linked=\"FDA approved Sonoma&#39;s antimicrobial claim for Alevicyn gel products for management of atopic dermatitis\" data-tweet=\"$SNOA - FDA approved Sonoma&#39;s antimicrobial claim for Alevicyn gel products for management of atopic dermatitis https://seekingalpha.com/news/3316308-fda-approved-sonomas-antimicrobial-claim-for-alevicyn-gel-products-for-management-of-atopic?source=tweet\" data-url=\"https://seekingalpha.com/news/3316308-fda-approved-sonomas-antimicrobial-claim-for-alevicyn-gel-products-for-management-of-atopic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316307\" data-ts=\"1512480157\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RVNC\" target=\"_blank\">RVNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316307-revances-rt002-successful-in-late-stage-studies-shares-ahead-25-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Revance&#39;s RT002 successful in late-stage studies; shares ahead 25% premarket</a></h4><ul><li>Thinly traded Revance Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/RVNC' title='Revance Therapeutics, Inc.'>RVNC</a>) is up&nbsp;<font color='green'>25%</font>&nbsp;premarket on increased volume on the heels of its <a href=\"https://seekingalpha.com/pr/17018059-revance-s-rt002-meets-primary-secondary-endpoints-achieves-6-month-duration-pivotal-sakura\" target=\"_blank\">announcement</a> of positive results from two Phase 3 clinical trials, SAKURA 1 and SAKURA 2, assessing DaxibotulinumtoxinA for Injection (RT002) for improving moderate-to-severe glabellar lines (frown lines). Both met their primary endpoints.</li><li>The company says DaxibotulinumtoxinA, if approved by the FDA, will be the first long-acting (six months) neuromodulator available in the U.S. Commercially available neuromodulators have a three-to-four-month duration of action for treating glabellar lines.</li><li>A long-term safety study, SAKURA 3, is fully enrolled and should be competed in H2 2018.</li><li>A U.S. marketing application should be filed in H1 2019 with market launch to follow in 2020.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316307\" data-linked=\"Revance&#39;s RT002 successful in late-stage studies; shares ahead 25% premarket\" data-tweet=\"$RVNC - Revance&#39;s RT002 successful in late-stage studies; shares ahead 25% premarket https://seekingalpha.com/news/3316307-revances-rt002-successful-in-late-stage-studies-shares-ahead-25-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316307-revances-rt002-successful-in-late-stage-studies-shares-ahead-25-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316306\" data-ts=\"1512480153\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HDS\" target=\"_blank\">HDS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316306-hd-supplyplus-7-after-beating-expectations\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HD Supply +7% after beating expectations</a></h4><ul><li>Adjusted net income of $149M, or $0.80 per diluted share vs. $94M, or $0.47 per diluted share in the same quarter a year ago.</li><li>Sales by segment: Facilities Maintenance +4.1%; Construction &amp; Industrial +11.8%.</li><li>Adjusted EBITDA increased 13.8% to $214M, compared to $188M in the third quarter of fiscal 2016.</li><li>FQ4 outlook: Net sales of $1.142B-$1.182B; Adjusted EBITDA of $135M-$147M; Adjusted net income of $0.41-$0.47.</li><li><a href='https://seekingalpha.com/symbol/HDS' title='HD Supply'>HDS</a> <font color='green'>+7%</font> premarket</li><li><a href=\"https://seekingalpha.com/news/3316243-hd-supply-beats-0_04-beats-revenue\" target=\"_blank\">FQ3 results</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3316306\" data-linked=\"HD Supply +7% after beating expectations\" data-tweet=\"$HDS - HD Supply +7% after beating expectations https://seekingalpha.com/news/3316306-hd-supplyplus-7-after-beating-expectations?source=tweet\" data-url=\"https://seekingalpha.com/news/3316306-hd-supplyplus-7-after-beating-expectations\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316305\" data-ts=\"1512480053\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAC\" target=\"_blank\">BAC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316305-bofa-adds-5b-to-buyback-shares-up-1-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofA adds $5B to buyback; shares up 1% premarket</a></h4><ul><li>The previous plan was for $12B in buybacks from July 1, 2017-June 30, 2018. Berkshire Hathaway, however, exercised its warrants this summer, buying 700M common shares at $7.14 each, or roughly $5B.</li><li>The additional $5B buyback - approved by the Fed - would theoretically allow the bank to buy back about 172M shares at yesterday's closing of $29.06.</li><li>Source: <a href=\"https://seekingalpha.com/pr/17018234-bank-america-increases-planned-common-stock-repurchase-program\" target=\"_blank\">Press Release</a></li><li><a href='https://seekingalpha.com/symbol/BAC' title='Bank of America Corporation'>BAC</a>&nbsp;<font color='green'>+1%</font>&nbsp;premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3316305\" data-linked=\"BofA adds $5B to buyback; shares up 1% premarket\" data-tweet=\"$BAC - BofA adds $5B to buyback; shares up 1% premarket https://seekingalpha.com/news/3316305-bofa-adds-5b-to-buyback-shares-up-1-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3316305-bofa-adds-5b-to-buyback-shares-up-1-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>85&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316303\" data-ts=\"1512479937\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VOD\" target=\"_blank\">VOD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316303-vodafone-and-softbank-announce-strategic-alliance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Vodafone and SoftBank announce strategic alliance</a></h4><ul><li>        Vodafone (NASDAQ:<a href='https://seekingalpha.com/symbol/VOD' title='Vodafone Group Plc'>VOD</a>) and SoftBank (<a href='https://seekingalpha.com/symbol/SFTBF' title='SoftBank Group'>OTCPK:SFTBF</a>, <a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a>) <a href=\"https://www.softbank.jp/en/corp/group/sbm/news/press/2017/20171205_02/\" target=\"_blank\">announce</a> a mobile services strategic alliance for enterprise customers.</li><li>               The alliance will enhance commercial and operational support for Vodafone&rsquo;s Japan-based multinational enterprise customers.&nbsp;</li><li>               No financial terms disclosed.&nbsp;</li><li>               Vodafone shares are&nbsp;<font color='green'>up 0.23%</font>&nbsp;premarket.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316024-softbank-intuitive-announce-ai-iot-collaboration\" target=\"_blank\">SoftBank and Intuitive announce AI and IoT collaboration</a> (Dec. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3316303\" data-linked=\"Vodafone and SoftBank announce strategic alliance\" data-tweet=\"$VOD $VOD $SFTBF - Vodafone and SoftBank announce strategic alliance https://seekingalpha.com/news/3316303-vodafone-and-softbank-announce-strategic-alliance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316303-vodafone-and-softbank-announce-strategic-alliance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316297\" data-ts=\"1512479239\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRAN\" target=\"_blank\">FRAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316297-francescas-lower-on-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Francesca&#39;s lower on earnings miss</a></h4><ul>     <li>Francesca's (NASDAQ:<a href='https://seekingalpha.com/symbol/FRAN' title='Francesca&#39;s Holdings Corp.'>FRAN</a>)&nbsp;reports comparable sales decreased 18% in <a href=\"https://seekingalpha.com/pr/17018064-francesca-s-reports-third-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Q3</a>, primarily due to a decline in boutique traffic and conversion rates.</li>     <li>Merchandise category sales:&nbsp;Apparel: $54.66M (-15%); Jewelry: $22.83M (-13%);&nbsp;Accessories: $15.36M (-11%);&nbsp;Gifts: $10.92M (-6%).</li>     <li>Gross margin rate dropped 860 bps to 39.6%, due to a decrease in merchandise margin and deleveraging of occupancy costs.</li>     <li>SG&amp;A expense rate grew 410 bps to 39.1%.</li>     <li>Operating margin rate squeezed 1280 bps to 0.4%.</li>     <li>Inventory -9.2% Y/Y to $38.82M.</li>     <li>Boutique count +45 Y/Y to 714.</li>     <li><b>Q4 Guidance</b>:&nbsp;Net sales: $145M to $150M; Comparable sales:&nbsp;-9% to -12%; EPS:&nbsp;$0.35 to $0.40.</li>     <li><b>FY2017 Guidance</b>: Net sales: $478M to $483M;&nbsp;Comparable-store -9% to -10%;&nbsp;EPS: $0.67 to $0.72; Shares outstanding: 36.3M; Tax&nbsp;rate: 38.7%;&nbsp;Capital expenditure: $30M to $33M; New boutiques: 60.</li>     <li>FRAN&nbsp;<font color='red'>-7.69%</font>&nbsp;premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3316297\" data-linked=\"Francesca&#39;s lower on earnings miss\" data-tweet=\"$FRAN - Francesca&#39;s lower on earnings miss https://seekingalpha.com/news/3316297-francescas-lower-on-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3316297-francescas-lower-on-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316285\" data-ts=\"1512477652\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIII\" target=\"_blank\">GIII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316285-g-iii-apparel-raises-fy2018-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G-III Apparel raises FY2018 guidance</a></h4><ul><li>G-III Apparel (NASDAQ:<a href='https://seekingalpha.com/symbol/GIII' title='G-III Apparel Group, LTD.'>GIII</a>) reports net sales rose 16% in <a href=\"https://seekingalpha.com/pr/17017976-g-iii-apparel-group-ltd-announces-third-quarter-fiscal-2018-results\" target=\"_blank\">Q3</a>&nbsp;as it includes net sales of DKNY and Donna Karan products.</li><li>Gross margin rate improved 170 bps to 38.1%.</li><li>SG&amp;A expense rate up 130 bps to 23.7%.</li><li>Operating margin rate expanded 80 bps to 13.8%.</li><li>Inventory +20.8% to $592.82M.</li><li><b>FY2018 Guidance</b>:&nbsp;Net sales: ~$2.8B; D&amp;A: $40M;&nbsp;Interest and financing charges, net: $45M; Income tax expense: $38M to $41M;&nbsp;Net income: $66M to $71M; Diluted EPS: $1.33 to $1.43; Adjusted net income: ~$71M to $76M; Adjusted EPS: $1.42 to $1.52; Adjusted EBITDA: $188M to $196M.</li><li>GIII&nbsp;<font color='green'>+4.98%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316285\" data-linked=\"G-III Apparel raises FY2018 guidance\" data-tweet=\"$GIII - G-III Apparel raises FY2018 guidance https://seekingalpha.com/news/3316285-g-iii-apparel-raises-fy2018-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3316285-g-iii-apparel-raises-fy2018-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:40 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316284\" data-ts=\"1512477514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HMNY\" target=\"_blank\">HMNY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316284-moviepass-owner-falls-after-cinemark-unveils-subscription-plan\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoviePass owner falls after Cinemark unveils subscription plan</a></h4><ul> <li>Shares of Helios and Matheson Analytics (NASDAQ:<a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a>) fall in premarket trading after Cinemark launches a monthly movie membership program.</li><li>The pricing on the Cinemark plan is $8.99 per month.</li> <li>HMNY <font color='red'>-6.90%</font> premarket to $11.20 vs. a 52-week trading range of $2.20 to $38.85.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3316271-cinemark-unveils-movie-membership-program\" target=\"_blank\">Cinemark unveils movie membership program</a> (Dec. 5)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3316284\" data-linked=\"MoviePass owner falls after Cinemark unveils subscription plan\" data-tweet=\"$HMNY - MoviePass owner falls after Cinemark unveils subscription plan https://seekingalpha.com/news/3316284-moviepass-owner-falls-after-cinemark-unveils-subscription-plan?source=tweet\" data-url=\"https://seekingalpha.com/news/3316284-moviepass-owner-falls-after-cinemark-unveils-subscription-plan\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>50&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3316277\" data-ts=\"1512476863\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AZO\" target=\"_blank\">AZO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3316277-autozone-higher-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AutoZone higher on earnings beat</a></h4><ul><li>AutoZone (NYSE:<a href='https://seekingalpha.com/symbol/AZO' title='AutoZone, Inc'>AZO</a>) reports domestic same-store sales rose 2.3% in <a href=\"https://seekingalpha.com/pr/17017973-autozone-1st-quarter-store-sales-increase-2_3-percent-eps-increases-6_8-percent-10_00\" target=\"_blank\">Q1</a>.</li><li>Total auto parts sales grew 5% to $2.51B.</li><li>Total domestic commercial sales advanced 6.7% to $491.25M.</li><li>Gross profit rate up 10 bps to 52.8%.</li><li>Merchandise inventories&nbsp;+6.3% Y/Y to $4.01B.</li><li>Domestic store count +167 Y/Y to 5,480.</li><li>Store count +214 Y/Y to 6,049.</li><li>AZO&nbsp;<font color='green'>+6.37%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3316277\" data-linked=\"AutoZone higher on earnings beat\" data-tweet=\"$AZO - AutoZone higher on earnings beat https://seekingalpha.com/news/3316277-autozone-higher-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3316277-autozone-higher-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}